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Vorwort 
 
Die vorliegende Habilitationsarbeit umfasst Arbeiten, welche ich im Laufe meiner 
kontinuierlichen Forschungsarbeiten auf dem Gebiet der molekularen Regulation von Tissue 
Factor während der letzten Jahre angefertigt habe. 
 
Die nachfolgend aufgeführten 4 Originalarbeiten werden als kumulative Habilitationsschrift 
eingereicht. In der vorstehenden Synopsis sollen diese in den Kontext vergangener und 
aktueller Forschung auf diesem Gebiet gestellt, sowie ihre Bedeutung für das aktuelle 
Verständnis und für weitere klinische und grundlagenwissenschaftliche Arbeiten dargelegt 
werden.  
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Summary 
 
Introduction 
Tissue factor (TF), formerly known 
as thromboplastin, is the key initiator of the 
coagulation cascade.1 The latter is triggered 
as soon as TF comes into contact with 
circulating activated factor VII (VIIa) 
resulting in formation of the TF-FVIIa 
complex (Fig. 1). The TF-VIIa complex then 
activates factor IX, which in turn activates 
factor X. In an important step of the 
coagulation cascade, the complex of factor 
Xa, calcium, and Factor Va catalyzes the 
conversion of prothrombin to thrombin, 
leading to fibrin formation, platelet 
activation, and, ultimately, generation of a 
thrombus (Fig 1).  
Over the last decade TF, has been 
recognized to be involved in the 
pathogenesis of a plethora of cardiovascular 
diseases. Moreover, our understanding of the 
molecular regulation of TF expression in 
vascular cells has profoundly improved. The 
following summary will focus on the role of 
TF in acute coronary syndromes and in the pathogenesis of stent thrombosis. 
 
Role of tissue factor in acute coronary syndromes 
In acute coronary syndromes (ACS), an occlusive thrombus leads to complete 
cessation of epicardial blood flow, eventually resulting in the clinical sequelae of a 
myocardial infarction (Fig. 2). Various lines of evidence indicate that TF is importantly 
involved in the pathogenesis of ACS. Indeed, TF can be detected in various different cell 
types in atheromatous plaques including endothelial and vascular smooth muscle cells, as well 
as in the necrotic plaque core.1 Moreover, elevated levels of TF have been observed in 
atherectomy specimens as well as in plasma of patients with unstable angina.  
In addition to macrophages and T-lymphocytes, increasing evidence has been 
accumulating that mast cells may also be involved in the development of atherosclerotic 
lesions as well as in the pathogenesis of  ACS. Indeed, mast cell activation occurs as an 
inflammatory event in atherogenesis and may lead to plaque instability.2 Furthermore, mast 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Tissue factor (TF) – key initiator 
of the coagulation cascade. Modified 
from: Steffel et al., Circulation 2006. 
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cells are present at the site of vasospasm in patients with variant angina, suggestive of an 
involvement of histamine in coronary artery spasm.3 Importantly, previous studies have 
indicated that coronary artery spasm may in itself lead to thrombus formation and vascular 
occlusion. The exact link 
between thrombosis and 
vasospasm, however, remained 
elusive. We were able to 
demonstrate that histamine, a 
biogenic amine mainly released 
by mast cells, potently induces 
TF in endothelial cells.4 This 
induction occurred at the 
transcriptional level, and was 
mediated via activation of the 
MAP kinases p38, extracellular 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Mediators of histamine-induced tissue factor 
(TF) induction. See text for details.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Tissue factor (TF) in atherosclerotic plaque rupture.  
5-HT – Serotonine; CD40-L – CD40-ligand; CRP – C-reactive protein; EC – Endothelial 
cell; HA – Histamine; ox LDL – Oxidized low-density lipoprotein; MΦ – Macrophage; 
PDGF-BB – Platelet derived growth factor BB; TNF-α – Tumor necrosis factor alpha; 
VSMC – Vascular smooth muscle cell. From: Steffel et al., Circulation 2006. 
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signal-regulated kinase (ERK), and c-jun terminal NH2 kinase (JNK, Fig. 3). In contrast to 
these MAP kinases, the phosphatidylinositol 3 (PI-3) -kinase pathway is constitutively active 
in endothelial cells, leading to a suppression of basal endothelial TF expression. Stimulation 
with histamine led to an inhibition of the PI3 kinase pathway, and hence to an increase in TF 
expression. On the receptor level, histamine-induced TF expression was completely blocked 
by different H1-receptor antagonists, while H2-receptor blockade had no effect. The latter is in 
good accordance with numerous previous studies, indicating that most deleterious vascular 
effects of histamine including vasospasm and intimal thickening after acute arterial injury are 
mediated via the H1-receptor.  
In the inflammatory environment of atherogenesis, however, histamine is by far not 
the only active pathogen; indeed, various cytokines and mediators accumulate in the 
developing atherosclerotic plaque and are released upon plaque rupture (Fig. 3 and Fig. 4). In 
order to better understand the role of histamine in thrombus formation, we investigated the 
interplay between histamine and two other important mediators of thrombus formation, TNF-
α and thrombin. While both of these agents are renown for their potent TF inducing capacity, 
histamine resulted in a substantial potentiation of TNF-α-induced TF expression, whereas 
thrombin-induced TF expression was only slightly enhanced.5 We were able to show that this 
differential augmentation occurred due to differential activation of JNK, resulting in 
pronounced synergy between histamine and TNF-α at the subcellular level. These findings are 
in line with other observations indicating a remarkable synergy of histamine and TNF-α on 
vascular cells, including the induction of intracellular adhesion molecule 1 and E-selectin.6 
Similar to our previous observations, the augmentation in TF induction by histamine was 
completely abolished by H1-receptor antagonist pretreatment. This study hence adds to the 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Mediators of tissue factor (TF) induction.  
5-HT2a – 5-hydroxytryptamine2a receptor; asTF - Alternatively spliced tissue factor. 
CD40-L – CD40-ligand; H1 – Histamine H1-receptor; IL-1 – Interleukin-1; IL1-R – 
Interleukin-1 receptor; KDR – VEGF receptor-2; LPS – Lipopolysaccharide; PAR – 
Protease-activated receptor; TLR-4 – Toll-like receptor 4; TNF-α – Tumor necrosis factor 
alpha; VEGF – Vascular endothelial growth factor. From: Steffel et al., Circulation 2006. 
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evidence that histamine and TNF-α effectively interact in endothelial activation as well as in 
vascular inflammation.  
Taken together, these two studies demonstrate that histamine may be importantly 
involved in thrombus formation in acute coronary syndromes, both by directly inducing TF as 
well as by potentiating the induction of TF by other mediators. Indeed, histamine-induced TF 
expression may represent an important link between vasospasm and thrombosis. Since this 
effect is completely abolished by H1-receptor antagonists, our results may furthermore have 
interesting therapeutic implications indicating a potential role for H1-receptor blockers in the 
treatment of atherosclerotic vascular diseases. 
 
Role of tissue factor in stent thrombosis 
Once thrombotic vessel occlusion occurs in ACS, percutaneous coronary intervention 
(PCI) and stenting of the culprit lesion is the preferred invasive treatment.7 Drug-eluting 
stents (DES) release pharmacological substances into the vessel wall after deployment which 
inhibit vascular smooth muscle cells migration and proliferation, i.e. key elements in the 
pathogenesis of restenosis. Several clinical trials have shown that DES are superior to 
uncoated bare-metal stents (BMS), mainly based on a decrease in restenosis rates and major 
adverse cardiac events. Despite reduced restenosis rates, however, the occurrence of stent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Potential mechanisms of thrombogenesis in first-generation drug-eluting 
stents.   
EPC – Endothelial progenitor cells; TF – Tissue factor. From: Lüscher, Steffel et al., 
Circulation 2007. 
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thromboses have not decreased with DES as compared to BMS, and may even be higher in 
the former under certain circumstances.8 The reason for the discrepancy between reduced 
restenosis rates and possibly enhanced thrombosis rates with first-generation DES as 
compared to BMS is not entirely unraveled yet, but likely results from the different 
mechanism underlying these two entities. While in the former, migration and proliferation of 
vascular smooth muscle cells in the neointimal lead to gradual re-occlusion of the target 
lesion, stent thrombosis occurs as a result of acute activation of the coagulation cascade and 
sudden thrombotic stent occlusion. As a result, the clinical sequelae differ considerably, with 
increasing, “typical” angina pectoris resulting from restenosis as compared to a sudden, acute 
myocardial infarction resulting from stent thrombosis. As a result, stent thrombosis remains 
one of the most feared complications in interventional cardiology owing to its high morbidity 
and mortality. 
Several factors are associated with an increased risk of stent thrombosis: These include 
factors associated with the procedure itself (stent malapposition and/or underexpansion, stent 
length, number of implanted stents, and dissections), patient and lesion characteristics, stent 
design as well as, importantly,  premature cessation of antiplatelet drugs. Moreover, drugs 
loaded on DES may contribute significantly to the thrombogenicity of the stent by several 
mechanisms (Fig. 5). Importantly, these drugs are designed to inhibit migration and 
proliferation of vascular smooth muscle cells, thereby inhibiting an important process 
contributing to in-stent restenosis as outlined above. By the same intracellular mechanisms, 
however, they may equally inhibit endothelial cell migration and proliferation, and hence 
impede stent re-endothelialization. With the stent (i.e., a foreign body) exposed to the blood 
stream without a “protective” endothelial cover, activation of the coagulation cascade may 
readily occur. Furthermore, inhibition of endothelial progenitor cell homing to the site of stent 
implantation by the drugs loaded on DES may reduce endothelial cell coverage and 
subsequently increase stent thrombogenicity even further. 
Above and beyond inhibition of re-endothelialization, however, drugs loaded on DES 
may have other effects, which may contribute to DES thrombogenicity. In first-generation 
DES, rapamycin (sirolimus, a macrocyclic lacton), FK-506 (tacrolimus, a macrolide 
immunosuppressant) and paclitaxel (a microtubule-stabilizing drug) are frequently used for 
DES coating. We were able to demonstrate that both rapamycin and paclitaxel induce 
endothelial TF expression and surface activity, and potentiate TF induction by other mediators 
(i.e. thrombin and TNF-α).9, 10 The subcellular mechanisms, however, were distinctly different 
for the two drugs (Fig. 6). Rapamycin exerts most of its biological effects by binding to its 
intracellular receptor, FKBP-12, which in turn inhibits the activity of mTOR (mammalian 
target of rapamycin). The latter is a downstream target of the PI-3 kinase, which, as 
previously mentioned, exerts an inhibitory effect on endothelial TF expression. By inhibiting 
mTOR, rapamycin induced TF via a “disinhibition” of the PI-3 kinase pathway; in contrast, 
phosphorylation of the MAP kinases, which are equally important regulators of TF, remained 
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unaffected. Importantly, rapamycin-induced TF expression could be entirely blunted by FK-
506, which competitively binds to the same intracellular receptor (i.e., FKBP-12), but 
subsequently inhibits the phosphatase calcineurin without affecting mTOR. Consequently, 
FK-506 itself had no significant effect on TF expression. In subsequent in-vivo studies, we 
were able to confirm this hypothesis and demonstrate that treatment with rapamycin 
accelerates carotid artery vessel occlusion.11  
In contrast to rapamycin, the mechanism underlying TF-induction by paclitaxel was 
distinctly different. Indeed, the latter had no effect on the PI-3 kinase pathway at all, but 
instead potently and selectively activated c-Jun terminal NH2 kinase (JNK) while leaving 
phosphorylation of the MAP kinases p38 and ERK unaffected. Docetaxel, a related 
microtubule-stabilizing agent, exerted a similar effect on JNK activation and TF expression as 
paclitaxel, indicating that TF induction by paclitaxel depends on stabilization of microtubule 
bundles rather than being a substance-specific effect.  
In summary, both rapamycin and paclitaxel increase endothelial TF expression and 
surface activity, which may favor the development of thrombus formation after deployment of 
drug-eluting stents. Both rapamycin and paclitaxel potentiate TF induction by other 
inflammatory or pro-thrombotic mediators, indicating that this effect may be particularly 
pronounced in the inflammatory environment of an acute coronary syndrome. As rapamycin-
induced TF expression was blocked by FK-506, these data may have interesting implications 
for the design of future drug-eluting stents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Mechanism of rapamycin- and paclitaxel induced tissue factor (TF) 
expression.  
MKK – Map kinase kinases; JNK – C-jun terminal NH2 kinase; PI-3K – 
phosphatidylinositol-3 kinase; mTOR – Mammalian target of rapamycin. From: Lüscher, 
Steffel et al., Circulation 2007. 
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Conclusion 
 Tissue Factor, the main initiator of the coagulation cascade, is importantly involved in 
the pathogenesis of acute coronary syndromes. We were able to show that histamine induces 
TF in endothelial as well as in vascular smooth muscle cells, which is even further potentiated 
by interaction with other inflammatory mediators such as TNF-α. Furthermore, we 
demonstrated that rapamycin and paclitaxel, both substances used for drug-eluting stent 
coating, induce endothelial TF expression, which may favor the development of stent 
thrombosis, especially in the inflammatory setting of acute coronary syndromes. These 
findings enhance our knowledge of TF, both on the subcellular level and from a clinical point 
of view, and may have important therapeutic implications in the medical and invasive 
treatment of atherosclerotic vascular diseases. 
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Histamine Induces Tissue Factor Expression
Implications for Acute Coronary Syndromes
Jan Steffel, MD; Alexander Akhmedov, PhD; Helen Greutert;
Thomas F. Lüscher, MD; Felix C. Tanner, MD
Background—Histamine can induce coronary vasospasm, leading to variant angina and acute myocardial infarction.
However, the role of histamine in thrombus formation is ill defined. Hence, this study investigates whether histamine
induces tissue factor (TF) expression in vascular cells.
Methods and Results—Histamine (108 to 105 mol/L) induced TF expression in a concentration-dependent manner in
human aortic endothelial and vascular smooth muscle cells, whereas TF pathway inhibitor expression remained
unaffected. RT-PCR and Northern blotting revealed that histamine stimulated TF mRNA transcription, peaking at 1
hour. Protein expression increased 18-fold (P0.02) with a maximum at 5 hours, which was paralleled by a 4-fold
augmentation in surface activity (P0.01). These effects were completely prevented by pretreatment with the H1
receptor antagonists mepyramine (P0.0001), chlorpheniramine, and diphenhydramine but not the H2 receptor
antagonist cimetidine (PNS). Histamine induced a time-dependent, H1 receptor–mediated activation of p38 MAP
kinase (p38), p44/42 MAP kinase (ERK), and c-jun terminal NH2 kinase (JNK). Blocking of p38, ERK, or JNK with
SB203580 (P0.0001), PD98059 (P0.0001), or SP600125 (P0.0001), respectively, impaired histamine-induced TF
expression in a concentration-dependent manner. In contrast, histamine-stimulated TF expression was increased by
phosphatidylinositol 3-kinase inhibition with LY294002 or wortmannin, whereas it was not affected by Rho-kinase
inhibition with Y-27632 or hydroxyfasudil.
Conclusions—Histamine induces expression of TF, but not TF pathway inhibitor, in vascular cells via activation of the H1,
but not H2, receptor. This effect is mediated by the MAP kinases p38, ERK, and JNK. This observation may open novel
perspectives in the treatment of variant angina and acute coronary syndromes. (Circulation. 2005;112:341-349.)
Key Words: coagulation  coronary disease  endothelium  signal transduction  thrombosis
Histamine is a biogenic amine that is released by mastcells, endothelial cells, and aggregating platelets.1–3
Mast cell activation is involved in atherogenesis and coronary
artery disease.4,5 Indeed, an elevated number of mast cells has
been observed in coronary atherectomy specimens from
culprit lesions, eliciting acute coronary syndromes.6 Further-
more, an increased number of mast cells at the site of plaque
erosion or rupture was found in patients who died of
myocardial infarction.7 Thus, mast cell activation occurs as
an inflammatory event in atherogenesis and may be involved
in plaque instability.8,9 These observations suggest a role for
histamine in the pathogenesis of acute coronary syndromes.
Moreover, mast cells have been detected at the site of
vasospasm in patients with variant angina, indicating a role
for histamine in coronary artery spasm.10,11 The latter has
been implicated in the pathogenesis of thrombus formation
leading to vascular occlusion12,13; indeed, the combination of
vasoconstriction and thrombosis plays a major role in inter-
mittent coronary artery occlusion after thrombolysis.14
Hence, a dynamic interaction of atherosclerosis, vasospasm,
and thrombus formation may precede vascular occlusion in
acute coronary syndromes.
Tissue factor (TF), a 263-residue membrane-bound glycopro-
tein, is a key enzyme in the activation of coagulation; it binds
activated factor VII (FVIIa), which in turn activates factor X
(FX), ultimately leading to thrombin formation. Because TF
pathway inhibitor (TFPI) is the direct physiological inhibitor of
the TF/FVIIA complex, it can modulate the effect of TF on
initiation of coagulation. Initiation of coagulation plays a major
role in the pathogenesis of acute coronary syndromes. Accord-
ingly, TF can be detected in various cell types in atheromatous
plaques, including endothelial and vascular smooth muscle
cells.15 Furthermore, elevated levels of TF antigen and activity
have been detected in plasma and atherectomy specimens of
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patients with unstable angina.15 Thus, TF is involved in the
initiation and propagation of acute coronary syndromes.
In the present study, we show that histamine induces TF
expression and activity in human aortic endothelial cells
(HAECs) and human vascular smooth muscle cells
(HAVSMCs). This effect, mediated through activation of the
MAP kinase pathway, is completely abolished by H1 receptor
antagonists.
Methods
Cell Culture
HAECs and HAVSMCs were cultured as described.16 Cells were
grown to confluence in 6-cm culture dishes and rendered quiescent
for 24 hours before stimulation with histamine (Sigma). Mepyra-
mine, chlorpheniramine, diphenhydramine, and cimetidine (all from
Sigma) were added to the dishes 30 minutes before stimulation.
Y-27632, hydroxyfasudil, wortmannin, SB203580 (all from Sigma),
LY294002, PD98059 (both from Cell Signaling), and SP600125
(Calbiochem) were added 60 minutes before stimulation. To assess
cytotoxicity, a colorimetric assay for detection of lactate dehydro-
genase was used according to the manufacturer’s recommendations
(Roche). A commercially available limulus amoebocyte lysate assay
was used according to the manufacturer’s recommendations (Cam-
brex) to assess for potential contamination with endotoxin. For some
experiments, histamine and/or lipopolysaccharide (LPS) solutions
were heated in a boiling water bath for 1 hour before being added to
the cells.
Western Blot Analysis
Protein expression was determined by Western blot analysis. Cells
were lysed in 50 mmol/L TRIS buffer as described.16,17 Then, 40-g
samples were loaded and separated by 10% SDS-PAGE. Proteins
were transferred to a PVDF membrane (Millipore) by semidry
transfer. Equal loading was confirmed by Ponceau S staining.
Antibodies to human TF and TFPI (both from American Diagnos-
tica) were used at 1:2000 and 1:1000 dilution, respectively; antibod-
ies against phosphorylated p38 MAP kinase (p38), phosphorylated
p44/42 MAP kinase (ERK), and phosphorylated c-jun terminal NH2
kinase (JNK; all from Cell Signaling) were used at 1:1000, 1:5000,
and 1:1000 dilution, respectively. Antibodies against total p38, total
ERK, and total JNK (all from Cell Signaling) were used at 1:2000,
1:10 000, and 1:1000 dilution, respectively. Blots were normalized
to -tubulin expression (1:10 000 dilution; Sigma).
RT-PCR and Northern Blot Analysis
Total RNA was extracted from HAECs (1.5106 cells) with 1 mL
TRIzol Reagent (Invitrogen) according to the manufacturer’s recom-
mendations. Conversion of total cellular RNA to cDNA was carried
out with Moloney murine leukemia virus reverse transcriptase and
random hexamer primers (Amersham Biosciences) in a final volume
of 35 L using 4 g of RNA. The total cDNA pool obtained served
as a template for subsequent PCR amplification with TF (F3)
-specific primers (508 to 529 bp, 892 to 913 of F3 cDNA; NCBI No.
NM 001993).18 The PCR conditions were as follows: 25 L final
reaction containing 2.5 mmol/L MgCl2, 0.2 mmol/L dNTP, 10
mol/L of each primer, 2.5 L of dimethyl sulfoxide, 0.5 U of
TaKaRa Taq DNA polymerase (TaKaRa Biomedicals), and 2 L of
cDNA template by using the following cycling parameters: 94° for 3
minutes for 1 cycle, 94° for 1 minute, 60° for 30 seconds, 65° for 45
seconds, for a total of 35 cycles, followed by a final elongation step
at 65° for 5 minutes. S15 primers served as loading controls for PCR.
Products were separated by electrophoresis on a 1% agarose gel and
visualized with ethidium bromide.
Total RNA (15 to 20 g) per sample was analyzed by Northern
blotting. A 405-bp human TF cDNA (508 to 913 bp) fragment was
labeled with [-32P]dCTP (Amersham Biosciences) using the
Prime-It Kit (Stratagene) according to the manufacturer’s recom-
mendations. Afterward, the membrane was stripped and rehybridized
with a control probe against the housekeeping gene human -actin
(Clontech). Bands were visualized by autoradiography.
TF Surface Activity
TF surface activity was analyzed with a colorimetric assay (Ameri-
can Diagnostica) according to the manufacturer’s recommendations
with some modifications as described.19 Cells were grown in 6-well
plates; after stimulation, cells were washed twice with PBS, followed
by incubation with human FVIIa and FX at 37°, allowing the
formation of a TF/FVIIa complex at the cell surface. The TF/FVIIa
complex converted human FX to activated FX, which was measured
by its ability to metabolize a chromogenic substrate. Lipidated
human TF was used as a positive control to confirm that the results
obtained were in the linear range of detection (data not shown).
Statistical Analysis
Data are presented as meanSEM. An unpaired Student t test was
applied to compare 2 groups; ANOVA with Bonferroni’s correction
was used for 3 groups. A value of P0.05 was considered
significant.
Results
Histamine Stimulates TF Expression and Activity
in HAECs and HAVSMCs
Stimulation of HAECs with histamine (108 to 105 mol/L)
led to a concentration- and time-dependent induction of TF
expression up to 18-fold the basal level; a maximal effect was
observed with 105 mol/L histamine (Figure 1A) and after 5
hours (Figure 1B). Under such conditions, the level of TF
expression corresponded to more than one third of that
observed with 10 ng/mL tumor necrosis factor (TNF)-, a
known potent inducer of TF expression in vascular cells
(Figure 1D, left). Histamine also enhanced TF expression in
HAVSMCs; the maximal increase was 3-fold compared
with control conditions (Figure 1C), again corresponding to
more than one third of the effect of 10 ng/mL TNF- (Figure
1D, right).
TF expression is very sensitive to LPS. Therefore, a
limulus amoebocyte lysate assay was performed that did not
detect endotoxin in water or histamine samples (detection
limit of the test, 0.125 EU/mL; n3; data not shown).
Moreover, the influence of heat treatment on histamine-
induced TF expression was examined. Histamine is very heat
stable,20 whereas LPS is inactivated at least in part by boiling
for 1 hour.21 Boiling of histamine (105 mol/L) for 1 hour did
not affect its ability to induce TF (PNS; Figure 1E). In
contrast, boiling of LPS (100 ng/mL) for 1 hour reduced its
ability to induce TF expression by 81% (P0.0001). LPS
potentiated histamine-induced TF expression, whereas boil-
ing of LPS (100 ng/mL) plus histamine for 1 hour resulted in
a decrease in TF induction by 80% compared with unheated
control (n3; P0.0001; Figure 1E). When a lower concen-
tration of LPS (2 ng/mL) was added with histamine (105
mol/L), TF was reduced to the level observed after stimula-
tion with histamine alone (n3; data not shown), consistent
with the observation that lower concentrations of LPS are
more readily inactivated by heat treatment.21 Thus, in contrast
to histamine alone, boiling of LPS both alone and together
with histamine resulted in a significantly reduced TF induc-
tion. These results demonstrate that no significant contami-
nation of histamine solutions with LPS occurred and confirm
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that the observed induction of TF is due to the action of
histamine.
RT-PCR (Figure 2A) and Northern blot analysis (Figure
2B) revealed that TF mRNA was induced in a time-dependent
manner. Maximal upregulation was observed after 1 hour and
then declined within 5 hours.
The increase in endothelial TF protein expression was
reflected by a 4-fold increase in TF surface activity after
stimulation with 105 mol/L histamine for 5 hours (Figure
3A). TF surface activity of HAVSMCs was increased to
1.4-fold the basal level under these conditions (Figure 3B).
Omission of either FVIIa or FX was used as negative control
for the specificity of the enzymatic reaction. No measurable
increase in TF activity over background levels was observed
under such conditions (n3; PNS; data not shown).
Histamine Does Not Affect Expression of TFPI
TFPI is the direct physiological inhibitor of the TF/FVIIa
complex. Interestingly, stimulation with histamine did not
affect TFPI expression in HAECs (Figure 4A). As a control,
the same lysates were blotted for TF expression (Figure 4B),
revealing the typical pattern of TF induction in response to
histamine (Figure 1A).
Histamine-Induced TF Expression Is Mediated by
Activation of the H1 Receptor
Histamine is known to exert most of its actions on cells
through the H1 or H2 receptor. To determine the receptor
involved in histamine-induced TF expression, cells were
pretreated with the H1 receptor antagonists mepyramine (108
to 105 mol/L), chlorpheniramine (108 to 105 mol/L), or
diphenhydramine (108 to 105 mol/L) or with the H2 receptor
antagonist cimetidine (107 to 105 mol/L). Preincubation
with mepyramine completely abolished histamine-induced
TF expression in HAECs (Figure 5A, top); the same effect
was observed with chlorpheniramine and diphenhydramine
(Figure 5A, middle and lower, respectively). In contrast, TF
expression in response to histamine remained unaffected by
Figure 1. Histamine induces TF expres-
sion in HAECs and HAVSMCs. A, Con-
centration dependency of histamine-
induced TF expression in HAECs. Values
are given as fold increase over unstimu-
lated control. *P0.02 vs control. B,
Time dependency of histamine-induced
TF expression in HAECs. Values are
given as percentage of TF expression at
5 hours. C, Histamine-induced TF
expression in HAVSMCs. Values are
given as fold increase over unstimulated
control. *P0.02 vs control. D, Compari-
son of histamine- and TNF-–induced TF
expression in HAECs (left) and
HAVSMCs (right). *P0.01 vs histamine.
E, Heat treatment of histamine (left), LPS
(middle), and histamine plus LPS (right).
**P0.001. Blots are representative of
3 different experiments and are normal-
ized to -tubulin (aT) expression.
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preincubation with cimetidine (Figure 5B). Similarly, pre-
treatment of histamine-stimulated HAVSMCs with mepyra-
mine (105 mol/L; Figure 5C) significantly reduced TF
expression, whereas cimetidine (105 mol/L) did not (Fig-
ure 5D). Consistent with these observations, the histamine-
induced increase in TF surface activity was inhibited by
mepyramine (105 mol/L) in both HAECs (Figure 3A) and
HAVSMCs (Figure 3B). Basal expression of TF was
detected in HAVSMCs but not HAECs. A small increase in
basal TF expression in HAVSMCs occurred after addition
of both mepyramine (105 mol/L) and cimetidine (105
mol/L) in the absence of histamine; this effect was not
observed in HAECs. Lactate dehydrogenase release did not
reveal any cytotoxic effect of histamine, mepyramine,
chlorpheniramine, diphenhydramine, or cimetidine (n4;
PNS; data not shown).
H1-Receptor Activation Regulates TF Expression
via the MAP Kinase Pathway
MAP kinase activation regulates TF expression in response to
several mediators.22,23 To assess whether histamine can acti-
vate MAP kinases, HAECs were examined at different time
points after stimulation (Figure 6A). p38, ERK, and JNK
were transiently activated after stimulation with histamine
(105 mol/L). Maximal phosphorylation of p38 and ERK
occurred after 5 minutes and returned to basal levels within
30 and 60 minutes, respectively. Maximal phosphorylation of
JNK was observed after 15 minutes and declined to basal
levels within 60 minutes. No change in total expression of
p38, ERK, or JNK was observed at any time point. Blocking
of the H1 receptor with mepyramine (105 mol/L) completely
abolished activation of p38, ERK, and JNK (Figure 6B).
Again, total expression of the MAP kinases remained
unchanged.
To analyze the involvement of MAP kinases in histamine-
induced TF expression, we examined the effect of MAP
kinase inhibitors on TF induction. SB203580 (106 to 105
mol/L), a specific inhibitor of p38, reduced histamine-
induced TF expression in a concentration-dependent manner
to 17% of control (Figure 7A). Similarly, preincubation with
PD98059 (3107 to 3106 mol/L), a specific inhibitor of
ERK phosphorylation, decreased TF expression in a
Figure 2. Histamine induces TF mRNA in HAECs. Time-
dependent increase in TF mRNA expression is observed after
stimulation of HAECs with histamine (105 mol/L). A, Represen-
tative RT-PCR; B, representative Northern blot analysis. S15
and human -actin served as loading controls for RT-PCR and
Northern blot analysis, respectively. Blots are representative of 3
independent experiments.
Figure 3. Histamine increases TF surface activity in HAECs and
HAVSMCs. A, Histamine increases TF surface activity in HAECs.
Increase in activity is suppressed by mepyramine. *P0.01 vs
control; #P0.01 vs histamine. B, Histamine increases TF sur-
face activity in HAVSMCs. Increase in activity is impaired by
mepyramine. *P0.0001 vs control; #P0.01 vs histamine.
Figure 4. Histamine does not alter TFPI expression. A, Increas-
ing concentrations of histamine do not alter TFPI expression in
HAECs. Values are given as percent of unstimulated control. B,
As control, samples from A are blotted for TF expression,
revealing typical, concentration-dependent pattern of induction
as demonstrated in A. Data are representative of 3 different
experiments; all blots are normalized to -tubulin (aT)
expression.
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concentration-dependent manner to 38% of control (Figure
7B). Finally, SP600125 (107 to 106 mol/L), a specific
inhibitor of JNK, diminished histamine-induced TF expres-
sion to 44% of control (Figure 7C). No cytotoxic effect of
either of these drugs was observed at the concentrations used
(n3; PNS; data not shown).
The Rho pathway is involved in the regulation of
thrombin-induced TF expression. Therefore, the effect of
Rho-kinase inhibitors on histamine-induced TF expression
was examined. Pretreatment with Y-27632 (105 mol/L) or
hydroxyfasudil (105 mol/L) did not result in a significant
alteration of TF expression after stimulation with histamine
(105 mol/L; Figure 8A). Activation of the phosphatidylino-
sitol 3–kinase (PI3-kinase) pathway has been described in
thrombin-induced TF expression.22,24 Therefore, the effect of
PI3-kinase inhibitors on histamine-induced TF expression
was assessed. Pretreatment with LY294002 (5106 mol/L)
or wortmannin (107 mol/L) enhanced histamine-induced TF
expression (Figure 8B).
Discussion
The present study demonstrates that histamine induces a
concentration- and time-dependent increase in TF expression
in vascular cells. Biologically active TF is located at the cell
surface; indeed, stimulation of TF expression by histamine
was paralleled by enhanced TF surface activity. The increase
in the latter was less pronounced than that in TF protein
expression; the distribution of TF in several cellular compart-
ments or the expression of encrypted TF at the cell surface
may account for this difference.25,26 Unlike endothelial cells,
unstimulated vascular smooth muscle cells displayed a rela-
tively pronounced basal expression of TF, consistent with the
rapid formation of a localized nidus of coagulation after
endothelial denudation in vivo. This higher basal expression
Figure 5. Histamine H1 receptor, but not
H2 receptor, mediates induction of TF
expression and surface activity. A,
Mepyramine completely prevents
histamine-induced TF expression in
concentration-dependent manner in
HAECs (top). *P0.0001 vs histamine. A
similar effect is observed with chlorphe-
niramine (middle) and diphenhydramine
(bottom). B, Cimetidine does not affect
histamine-induced TF expression in
HAECs. C, Mepyramine impairs
histamine-induced increase in TF expres-
sion in HAVSMCs. *P0.0001 vs control;
#P0.0001 vs histamine; **P0.002 vs
control. D, Cimetidine does not affect
histamine-induced TF expression in
HAVSMCs. *P0.0001 vs control;
**P0.0002 vs control. Blots are repre-
sentative of 4 different experiments
except for pretreatment with chlorphe-
niramine (n2) and diphenhydramine
(n2). All blots are normalized to
-tubulin (aT) expression.
Steffel et al Histamine Induces Tissue Factor 345
in HAVSMCs may account for the observation that a maxi-
mal increase in both TF expression and activity after stimu-
lation with histamine was lower than in HAECs. The small
but significant increase in TF expression in HAVSMCs after
the addition of mepyramine or cimetidine compared with
control conditions was probably due to partial agonistic
activity of the respective antagonist.
TF expression is known to be regulated at the transcrip-
tional level in response to many stimuli.18,27 Consistent with
these observations, histamine induced TF mRNA transcrip-
tion in a time-dependent manner. Indeed, the kinetics of
mRNA induction in response to histamine were similar to
those observed with other mediators.27,28 Moreover, the
sequence of intracellular events after stimulation with hista-
mine is consistent with a logical order: The maximum MAP
kinase activation occurred after 5 to 15 minutes, RNA
expression peaked after 1 hour, and protein expression
reached its maximum after 5 hours.
Histamine-induced TF expression was compared with that
in response to TNF-, a known potent inducer of TF.16,26 In
both HAECs and HAVSMCs, histamine induced TF to more
than one third of the level observed after stimulation with 10
ng/mL TNF-. Because this concentration of TNF- is very
high, the effect of histamine compares well with that of the
classic inducer of TF expression.
At the cellular level, TF expression is counterbalanced by
TFPI. Several inducers of TF expression have been investi-
gated with respect to their ability to affect TFPI expression;
indeed, an increase, a decrease, or no alteration in TFPI
expression has been observed after endothelial stimulation
with TNF-, LPS, and 5-hydroxytryptamine.29–31 Stimulation
of HAECs with histamine did not affect TFPI expression;
thus, histamine-induced TF expression may result in partic-
ularly pronounced procoagulative changes because it is not
paralleled by an increase in TFPI.
TF expression in HAECs and HAVSMCs is mediated by
activation of the H1 receptor. Indeed, activation of this
receptor plays an important role in the pathogenesis of
cardiovascular disease. Vascular contractions to histamine are
mediated through activation of the H1 receptor.11,32
Histamine-induced P-selectin expression on endothelial cells,
a key step in leukocyte transmigration to the subendothelium,
also is mediated by this receptor.33 Moreover, chlorphenira-
mine, a specific H1 receptor blocker used in our study,
prevents lesion formation in a rabbit model of atherosclero-
sis,34 and the H1 receptor blocker diphenhydramine, but not
the H2-receptor blocker cimetidine, prevents intimal thicken-
ing after vascular injury.35 Consistent with these observa-
tions, expression of the H1 receptor is increased in endothelial
and vascular smooth muscle cells from atherosclerotic ves-
sels.36 Hence, the effect of histamine on TF expression adds
to the evidence that histamine-induced vascular dysfunction
is mediated through activation of the H1 receptor.
Histamine leads to activation of p38, ERK, and JNK via
the H1 receptor. Consistent with our observation, activation of
MAP kinases has been demonstrated in vascular cells in
response to histamine.37,38 Indeed, activation of p38 and ERK
is mediated through the H1 receptor in a smooth muscle cell
line.37 Other inflammatory agents such as TNF- are known
to activate all 3 MAP kinases in vascular cells.16,23 With
respect to TF expression, the pattern of MAP kinase activa-
tion in vascular cells is largely dependent on the specific
stimulus. p38 is involved in thrombin-induced TF expression
in endothelial cells.22 p38 and ERK mediate TNF-- and
vascular endothelial growth factor–induced TF expression in
endothelial cells.23 Furthermore, JNK mediates TF expression
in endothelial cells stimulated with TNF-.16 In contrast,
ERK, but not p38, regulates lysophosphatic acid–induced TF
expression in vascular smooth muscle cells.19 Interestingly, in
both LPS-stimulated monocytes and thrombin-stimulated en-
Figure 6. Histamine activates p38, ERK, and JNK via the H1 receptor. A, Histamine induces transient, time-dependent activation of
p38, ERK, and JNK. No change in expression of total levels of MAP kinases is observed. B, Blocking of H1 receptor with mepyramine
abolishes histamine-induced activation of p38, ERK, and JNK. Again, no change in expression of total levels of MAP kinases is
observed. Blots are representative of 3 different experiments.
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dothelial cells, TF expression occurs through activation of all
3 MAP kinase pathways.27,39 We show here that specific
inhibition of any of the 3 MAP kinases leads to a marked
reduction in histamine-induced TF expression in HAECs
even at low concentrations of the respective inhibitor. Thus,
similar to LPS-stimulated monocytes,27 activation of p38,
ERK, and JNK cooperatively regulates histamine-induced TF
expression in HAECs. Inhibition of p38 has beneficial effects
on cardiac ischemia, reperfusion, endothelial function, and
hypertensive end-organ damage.40,41 Hence, our study impli-
cates that inhibiting MAP kinases might represent a potential
target for the treatment of thrombotic vascular disease.
Nevertheless, the use of MAP kinase inhibitors in vivo is still
controversial and requires further study.41,42
RhoA activation plays a major role in thrombin-induced
TF expression in HAECs.22,24 Indeed, histamine exerts some
of its effects on endothelial cells through activation of the
Rho pathway.43,44 Surprisingly, Rho-kinase inhibition did not
alter TF expression in response to histamine. Hence, the Rho
pathway does not seem to be involved in histamine-induced
TF expression. Indeed, RhoA activation may be affected by
the cell type and/or the specific stimulus involved; alterna-
tively, cell culture conditions may play a role, as has been
implied in the regulation of cell permeability by hista-
mine.43,44 PI3-kinase inhibition enhances thrombin- and TNF-
–stimulated TF expression in endothelial cells and mono-
cytes, respectively.22,24,27 Consistent with these observations,
histamine-induced TF expression was further increased after
inhibition of PI3-kinase. Hence, similar to TF expression
stimulated by other mediators, the PI-3 kinase pathway also
plays a negative regulatory role in histamine-induced TF
expression.
Histamine is released from mast cells, endothelial cells,
and activated platelets and elicits potent arterial contrac-
tions.1–3,11,32,45 Vasospasm mainly occurs in coronary arteries
exhibiting some atherosclerotic changes and is promoted by
the presence of mast cells and dysfunctional endothelial cells.
Coronary artery vasospasm is involved in variant angina and
has been implicated in coronary artery thrombus forma-
tion.12–14 The latter is indeed crucial for the pathogenesis of
arterial occlusion, and TF is a key enzyme for its initiation.
As histamine induces TF expression, the release of the amine
from mast cells or endothelial cells may represent an explan-
tation for the frequent simultaneous occurrence of atheroscle-
rosis, vasospasm, and thrombus formation. Moreover, the
release of histamine from aggregating platelets may function
as a positive feedback mechanism, further enhancing TF
expression and thus thrombus formation. Interestingly, hista-
mine levels are increased in platelets from patients with
peripheral artery disease.46
Augmented TF expression in HAECs and HAVSMCs after
stimulation with histamine is consistent with atherosclerosis
as an inflammatory disease.9,15 Indeed, elevated levels of TF
have been observed in patients with hypertension, dyslipid-
emia, diabetic vasculopathy, and peripheral artery dis-
ease.15,47–50 Not surprisingly, TF has also been implicated in
coronary artery disease and acute myocardial infarction.15
Here, we show that H1 receptor antagonists completely
abolish histamine-induced TF expression in HAECs. Hence,
Figure 7. Inhibition of p38, ERK, and JNK impairs histamine-
induced TF expression. A, SB203580, specific inhibitor of p38 acti-
vation, impairs histamine-induced TF expression. #P0.02,
*P0.0001 vs histamine. B, PD98059, specific inhibitor of ERK
activation, impairs histamine-induced TF expression. *P0.0001 vs
histamine. C, SP600125, specific inhibitor of JNK activation,
impairs histamine-induced TF expression. #P0.01, *P0.0001 vs
histamine. No change in basal TF expression is observed after
application of SB203580, PD98059, or SP600125 compared with
unstimulated control. Blots are representative of 4 different experi-
ments; all blots are normalized to -tubulin (aT) expression.
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our findings suggest a therapeutic potential of H1 receptor
antagonists in the treatment of acute coronary syndromes.
In summary, histamine-induced TF expression may medi-
ate thrombus formation in atherogenesis, especially in inflam-
mation and vasospasm, implicating interesting novel perspec-
tives for the treatment of vascular occlusive diseases such as
acute coronary syndromes.
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Summary. Background: Histamine plays an important role
in vascular disease. Tissue factor (TF) expression is induced
in vascular inﬂammation and acute coronary syndro-
mes. Objectives: This study examined the eﬀect of histamine
on tumor necrosis factor-a- (TNF-a-) vs. thrombin-induced
endothelial TF expression. Methods and results: Histamine
(10)8–10)5 mol L)1), TNF-a (5 ng mL)1), and thrombin
(1 U mL)1) induced TF expression in human endothelial cells.
AlthoughTFexpressionbyTNF-a and thrombinwas identical,
histamine augmented TNF-a-induced expression 7.0-fold, but
thrombin-induced expression only 2.6-fold. Similar responses
occurred with TF activity. The H1-receptor antagonist mepyr-
amine abrogated these eﬀects. Diﬀerential augmentation by
histamine was also observed at the mRNA level. Histamine-
induced p38 activation preceded a weak second activation to
both TNF-a and thrombin. Histamine-induced c-Jun NH2-
terminal kinase (JNK) activation was followed by a strong
second activation to TNF-a, and less to thrombin. Selective
inhibition of this second JNK activation by SP600125 reduced
TF induction to histamine plus TNF-a by 67%, but to
histamine plus thrombin by only 32%. Histamine augmented
TNF-a- and thrombin-induced vascular cell adhesion molecule
1 (VCAM-1) expression to a similar extent. Consistent with this
observation, VCAM-1 induction to TNF-a and thrombin was
mediated by p38, but not by JNK. Conclusions: Histamine
diﬀerentially augments TNF-a- vs. thrombin-induced TF
expression and activity, which is mediated by the H1-receptor,
occurs at the mRNA level, and is related to diﬀerential JNK
activation.
Keywords: inﬂammation, mitogen-activated protein kinase,
signal transduction, thrombosis, tissue factor, vascular cell
adhesion molecule-1.
Introduction
Histamine is involved in vascular inﬂammation and is released
by mast cells, endothelial cells, and aggregating platelets [1–3].
Mast cell activation occurs in atherogenesis and coronary
artery disease [4–7]; these cells are detected at high numbers in
atherosclerotic plaques and also in coronary atherectomy
specimens from patients with acute myocardial infarction [8,9].
Consistent with a role of histamine in vascular disease, mice
deﬁcient in histidine decarboxylase, the rate-limiting enzyme
for histamine formation, exhibit reduced intimal thickening
with a lower intima-to-media ratio after vascular injury [10].
Moreover, histidine decarboxylase and the histamine H1-
receptor are both expressed in atherosclerotic human coronary
arteries, and granulocyte–macrophage colony-stimulating fac-
tor induces their expression in monocytes [11]. Activated mast
cells also secrete other mediators known to play a role in
inﬂammation and atherogenesis, such as tumor necrosis factor-
a (TNF-a), so that concomitant release of histamine and TNF-
a may well occur under these conditions [5].
Tissue factor (TF) is a key protein in the activation of
coagulation and plays an important role in the pathogenesis of
thrombotic diseases like acute coronary syndromes [12].
Indeed, TF antigen and activity are elevated in plasma and
atherectomy specimens of patients with unstable angina.
Moreover, TF may be involved in the pathogenesis of
atherosclerosis, and different cell types in atherosclerotic
plaques including endothelial cells exhibit a pronounced
expression of TF [12]. In the inﬂammatory environment of
atherosclerotic vessels, endothelial TF expression and activity is
induced by mediators such as histamine and TNF-a [13]. As
both mediators are released by mast cells, interactions of
histamine with TNF-a regarding TF induction are likely
to occur. Thrombin not only catalyzes the conversion of
ﬁbrinogen to ﬁbrin, but also induces TF as a positive feedback
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mechanism. Therefore, interactions of histaminewith thrombin
may be important for regulation of TF expression as well.
This study was designed to investigate interactions
of histamine with TNF-a vs. thrombin in endothelial TF
expression.
Materials and methods
Cell culture
Human aortic endothelial cells (HAEC) were cultured as
described [14]. Cells were grown to conﬂuence in 6-cm culture
dishes and rendered quiescent for 24 h before stimulation with
histamine, TNF-a, or thrombin (all from Sigma, Munich,
Germany). Histamine was preincubated for 1 h before stimu-
lation with TNF-a or thrombin. Mepyramine and cimetidine
(both from Sigma) were added to the dishes 30 min prior to
stimulation. SB203580 was obtained from Sigma, SP600125
from Calbiochem (San Diego, CA, USA). To assess cyto-
toxicity, a colorimetric assay for detection of lactate dehydro-
genase was used according to the manufacturer’s
recommendations (Roche, Mannheim, Germany).
Western blot analysis
Protein expression was determined by Western blot analysis as
described [14,15]. Forty micrograms samples was separated by
10% sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS–PAGE), and proteins were transferred to PVDF mem-
branes (Millipore, Billerica, MA, USA) by semidry transfer.
Antibodies against human TF (American Diagnostica, Pfungs-
tadt, Germany) and human vascular cell adhesion molecule-1
(VCAM-1; R&D, Abingdon, UK) were used at 1:2000
dilution. Antibodies against phosphorylated p38 mitogen-
activated protein kinase (MAPK) (p38) and phosphorylated c-
Jun NH2-terminal kinase (JNK; both from Cell Signaling,
Allschwil, Switzerland) were used at 1:1000 dilution. Antibod-
ies against total p38 (Cell Signaling) and total JNK (Cell
Signaling and Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) were used at 1:2000 dilution. Blots were normalized to
alpha-tubulin (aT) expression (1:10 000 dilution, Sigma).
Real time reverse transcriptase-polymerase chain reaction
Extraction of RNA fromHAEC and conversion to cDNAwas
performed as described [13]. Real-time PCR was carried out in
an MX3000P PCR cycler (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s instructions. All PCR experi-
ments were performed using the SYBR Green JumpStart kit
(Sigma). Each reaction (25 lL) contained 2 lL of cDNA,
1 pmol of each primer, 0.25 lL of internal reference dye, and
12.5 lL of JumpStart Taq ReadyMix (buffer, dNTPs, stabi-
lizers, SYBR Green, Taq polymerase, and JumpStart Taq
antibody). Primers for TF mRNA were used as described
[13,16]. Primers for human L28: sense primer: 5¢-GCATCTG-
CAATGGATGGT-3¢; antisense primer: 5¢-
TGTTCTTGCGGATCATGTGT-3¢. The ampliﬁcation pro-
gram consisted of 1 cycle at 95 C for 10 min, followed by 40
cycles with a denaturing phase at 95 C for 30 s, an annealing
phase at 60 C for 1 min, and an elongation phase at 72 C for
1 min. A melting curve analysis was performed after ampliﬁ-
cation to verify the accuracy of the amplicon. PCR products
were analyzed on an ethidium bromide stained 1% agarose gel
for veriﬁcation of the correct ampliﬁcation. In each real-time
PCR run for TF and L28, a calibration curve was included,
which was generated from serial dilutions of a known TF and
L28 standard, respectively.
Tissue factor surface activity
TF surface activity was analyzed using a colorimetric assay
(American Diagnostica) according to the manufacturer’s
recommendations with some modiﬁcations as described
[13,17]. Cells were grown in 12-well plates; after stimulation,
cells were washed twice with phosphate-buffered saline fol-
lowed by incubation with human factor (F) VIIa and FX at
37 , allowing for the formation of TF/FVIIa-complex at the
cell surface. TF/FVIIa-complex converted human FX to FXa,
which was measured by its ability to metabolize a chromogenic
substrate. Lipidated human TF was used as a positive control
to conﬁrm that the results obtained were in the linear range of
detection (data not shown).
Statistics
Data are presented asmean+/-SEM.Unpaired Student’s t-test
was applied for comparison of two groups. A P-value < 0.05
was considered signiﬁcant.
Results
Histamine differentially augments TNF-a- vs.
thrombin-induced TF protein expression and activity
Stimulation of HAEC with histamine (10)8–10)5 mol L)1)
induced TF protein expression in a concentration-dependent
manner up to eighteenfold above the basal level (Fig. 1A) [13].
When cells were pretreated with histamine for 1 h, TNF-a-
induced TF expression was augmented in a concentration-
dependent manner; the maximal effect was observed with
10)5 mol L)1 histamine and accounted for a 7.0-fold increase
in TF expression compared with TNF-a alone (Fig. 1B, left
panel). Histamine also augmented thrombin-induced TF
expression; in contrast to TNF-a, however, 10)5 mol L)1
histamine increased TF expression only 2.6-fold comparedwith
thrombin alone (Fig. 1B, right panel). Consistent with this
observation, histamine concentrations as low as 10)8 and
10)7 mol L)1, which did not affect TF expression on their own,
augmented TF expression in response to TNF-a, but not to
thrombin (Fig. 1B). Direct comparison of the maximal hista-
mine effect revealed a 3.5-fold higher augmentation of TNF-a
as compared with thrombin-induced TF expression (Fig. 1C).
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Importantly, the levels of TF induction by TNF-a alone vs.
thrombin alone were identical (P ¼ NS; Fig. 1B,C).
Similar to the pattern of TF protein expression, histamine
differentially affected TF surface activity; the amine aug-
mented TNF-a-induced TF activity 3.0-fold, but thrombin-
induced activity only 1.7-fold (Fig. 1D). TF surface
activity induced by TNF-a alone vs. thrombin alone was
identical.
Histamine augments TNF-a- and thrombin-induced TF
expression via the H1-receptor
Histamine induces TF expression via the H1-receptor [13]. The
effect of histamine on both TNF-a- (Fig. 2A) and thrombin-
induced TF expression (Fig. 2B) was abolished bymepyramine
(10)5 mol L)1), a selective H1-receptor blocker, and no differ-
ence in TF expression was observed under these conditions
compared with stimulation with TNF-a or thrombin alone
(P ¼ NS).
Histamine differentially augments TNF-a- vs.
thrombin-induced TF mRNA expression
The maximal increase of both TNF-a- and thrombin-induced
TF protein expression was observed between 3 and 5 h
(Fig. 3A). The augmenting effects of histamine on TNF-a-
and thrombin-induced TF protein expression were maximal at
the same time points (Fig. 3A). However, the effect of
histamine on TNF-a-induced TF expression was severalfold
higher than that on thrombin-induced expression at all time
points examined (Fig. 3A).
Fig. 1. Histamine diﬀerentially augments tumor necrosis factor-a- (TNF-a-) vs. thrombin-induced tissue factor (TF) protein expression and activity. (A)
Histamine induces TF expression. Values are given as fold-increase over control. *P < 0.01 vs. control. (B) Left panel: histamine augments TNF-a-
induced TF expression. *P < 0.002, #P < 0.005, **P < 0.0001 vs. TNF-a alone. Right panel: histamine augments thrombin-induced TF expression.
*P < 0.005 vs. thrombin alone. (C) Histamine diﬀerentially augments TNF-a- vs. thrombin-induced TF expression. **P < 0.0001 vs. TNF-a alone and
P < 0.0001 vs. thrombin plus histamine; *P < 0.02 vs. thrombin alone. (D) Histamine diﬀerentially augments TNF-a- and thrombin-induced TF surface
activity. **P < 0.0001 vs. TNF-a alone and P < 0.001 vs. thrombin plus histamine; *P < 0.02 vs. thrombin alone. Cells were pretreated with histamine
for 1 h before stimulation with TNF-a or thrombin for 5 h. Values are representative of four independent experiments except for TF surface activity (n ¼
3). Blots are normalized to alpha tubulin expression.
Fig. 2. Histamine augments tumor necrosis factor-a- (TNF-a-) and
thrombin-induced tissue factor expression via the H1-receptor. Mepyr-
amine prevents the eﬀect of histamine on (A)TNF-a-induced and (B)
thrombin-induced TF expression. *P < 0.05 vs. TNF-a plus histamine
and *P ¼ NS vs. TNF-a alone. Cells were pretreated with mepyramine
for 1 h, followed by histamine for 1 h, and then stimulated with TNF-a or
thrombin for 5 h. Values are representative of three (TNF-a) and two
(thrombin) independent experiments. Blots are normalized to alpha
tubulin expression.
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Real-time PCR analysis revealed that histamine augmented
TNF-a-induced TF mRNA levels by 3.9-, 4.4-, and 2.6-fold
after 2, 3, and 5 h of stimulation, respectively; in contrast, the
amine augmented thrombin-induced TF levels by only 2.1-,
1.7-, and 1.6-fold after 2, 3, and 5 h of stimulation, respectively
(Fig. 3B). Maximal expression of TF mRNA occurred after
2 h of stimulation under all conditions examined. Direct
comparison of histamine’s maximal effect revealed a 1.9-fold
higher augmentation of TNF-a as compared with thrombin-
induced TF mRNA levels (Fig. 3B).
TNF-a and thrombin differentially activate p38 and JNK after
pretreatment with histamine
To analyze the role of p38 and JNK activation, HAEC were
pretreated with either histamine (Fig. 4A, B, right panel) or
carrier (H2O; Fig. 4A, B, left panel) for 1 h before stimulation
with TNF-a or thrombin. Histamine elicited a transient
activation of p38 and JNK within the ﬁrst hour of treatment
(Fig. 4A, B) [13]. TNF-a alone and thrombin alone activated
p38 and JNK as well (Fig. 4A, B, left panel). The kinetics of
TNF-a- vs. thrombin-induced p38 phosphorylation were
similar, with maximal activation occurring after 15 min with
TNF-a and after 5 min with thrombin. Following preincuba-
tion with histamine, TNF-a and thrombin elicited a second
activation of p38, which was weaker than that induced by
histamine. In contrast to p38, the kinetics of JNK phosphory-
lation differed between TNF-a and thrombin: TNF-a activated
JNK peaking after 15 min, while thrombin caused a gradual
increase in JNK activation over 60 min (Fig. 4B, left panel).
The effect of histamine preincubation on JNK activation also
differed between TNF-a and thrombin. After pretreatment
with histamine, JNK activation by TNF-a was quite pro-
nounced, in comparison with both histamine alone and
histamine plus thrombin; in contrast, JNK activation by
thrombin was markedly weaker under these conditions
(Fig. 4B, right panel).
JNK differentially mediates TNF-a- vs. thrombin-induced TF
expression after pretreatment with histamine
MAPKs mediate TF induction in response to stimulation with
histamine, TNF-a, and thrombin [13,14,18–20]. Inhibition of
p38 by SB203580 and JNK by SP600125 decreased TNF-a-
induced TF expression by 72% and 49%, respectively
(Fig. 5A), while thrombin-induced TF expressionwas inhibited
by 86% and 38%, respectively (Fig. 5B). Similarly, inhibition
of p38 and JNK reduced histamine-augmented TF expression
in response to TNF-a by 77% and 57%, respectively (Fig. 5C).
In contrast, histamine-augmented TF expression in response to
thrombin was reduced by 89% after inhibition of p38, but only
by 26% after inhibition of JNK (Fig. 5D).
While TNF-a potently activated JNK after pretreatment
with histamine, thrombin hardly affected JNK phosphoryla-
tion under the same conditions. Moreover, inhibition of JNK
reduced TF expression in response to TNF-a plus histamine to
a higher extent than that to thrombin plus histamine. To
evaluate the signiﬁcance of the second activation of JNK by
TNF-a vs. thrombin after pretreatment with histamine, the
JNK inhibitor SP600125 was added 45 min after stimulation
with histamine. Under these conditions, no reduction in TF
expression to histamine alone was observed (Fig. 6A). When
cells were stimulated with TNF-a or thrombin 60 min after
exposure to histamine (i.e. 15 min after treatment with
SP600125), histamine-augmented TF expression was reduced
by 67% in response to TNF-a (Fig. 6B), but only by 32% in
response to thrombin (Fig. 6C).
Histamine does not differentially augment TNF-a vs.
thrombin-induced VCAM-1 expression
Pretreatment with histamine augmented VCAM-1 expression
in response to TNF-a by 69% (Fig. 7A, left panel) and to
thrombin by 67% (Fig. 7A, right panel). Inhibition of p38 with
SB203580 reduced TNF-a-induced VCAM-1 expression by
Fig. 3. Histamine diﬀerentially augments tumor necrosis factor-a- (TNF-
a-) vs. thrombin-induced tissue factor (TF) mRNA expression. (A) Time
course of TF protein expression. Diﬀerential augmentation of TNF-a- vs.
thrombin-induced TF expression is observed at 3, 5, and 7 h. Values are
representative of three independent experiments and normalized to alpha
tubulin expression. (B) Time course of TF mRNA expression (real-time
polymerase chain reaction). Diﬀerential augmentation of TNF-a- vs.
thrombin-induced TF expression is observed at 2, 3, and 5 h. *P < 0.02;
**P < 0.001. Cells were pretreated with histamine for 1 h before stimu-
lation with TNF-a or thrombin for 5 h. Values are representative of four
diﬀerent experiments and normalized to L28 expression.
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Fig. 5. Inhibition of p38 and c-Jun NH2-terminal kinase (JNK) before pretreatment with histamine. (A) Tumor necrosis factor-a (TNF-a)-induced
tissue factor (TF) expression is decreased by speciﬁc inhibition of p38 (SB203580) or JNK (SP600125) phosphorylation. *P < 0.0001; #P < 0.01 vs.
TNF-a alone. (B) Thrombin-induced TF expression is decreased by inhibition of p38 or JNK phosphorylation. *P < 0.0001, #P < 0.05 vs. thrombin
alone. Cells were pretreated with the inhibitors for 1 h and then stimulated with TNF-a or thrombin for 5 h. (C) Histamine-augmented TF expression
to TNF-a is decreased by inhibition of p38 or JNK. **P < 0.0005 vs. histamine plus TNF-a. (D) Histamine-augmented TF expression to thrombin
is decreased by inhibition of p38 or JNK. Notably, the eﬀect of SP600125 is much less pronounced than in (C). **P < 0.0001, *P < 0.002 vs. histamine
plus thrombin. Cells were pretreated with the inhibitors for 1 h, followed by histamine for 1 h and then stimulated with TNF-a or thrombin for 5 h.
Blots are representative of at least three diﬀerent experiments and normalized to alpha tubulin expression. SB, SB203580 (10)5 mol L)1); SP, SP600125
(10)6 mol L)1).
Fig. 4. Tumor necrosis factor-a (TNF-a) and thrombin diﬀerentially activatemitogen-activated protein kinases after pretreatment with histamine. HAECs
are treated with carrier (H2O, left panel) or histamine (right panel) for 1 h and then stimulated with TNF-a or thrombin for the time points indicated.
Following treatment with histamine, the second wave of p38 activation by TNF-a or thrombin is weaker (A, right panel) than that without histamine
(A, left panel). The secondwave of c-JunNH2-terminal kinase (JNK) activation by TNF-a is quite pronounced, while that by thrombin ismarkedly weaker
(B). Time courses of stimulation with TNF-a and TNF-a plus histamine, as well as with thrombin and thrombin plus histamine, are each performed
and blotted in parallel, and blots are only separated for didactic reasons. There is no change in total protein expression of p38 and JNK. Blots are
representative of three independent experiments (except for time course of H2O stimulation [n ¼ 1] and time course of histamine stimulation [n ¼ 1], which
was described previously) [13].
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60%, while inhibition of JNK with SP600125 had no
signiﬁcant effect (Fig. 7B). Inhibition of p38 reduced throm-
bin-induced VCAM-1 expression by 83%, while inhibition of
JNK increased VCAM-1 expression (Fig. 7C). VCAM-1
expression in response to histamine plus TNF-a was reduced
by 25% after inhibition of p38, while inhibition of JNK had no
effect (Fig. 7D). VCAM-1 expression in response to histamine
plus thrombin was reduced by 59% after inhibition of p38,
while inhibition of JNK had no effect (Fig. 7E).
Discussion
This study demonstrates that histamine augments TNF-a-
induced endothelial TF expression and activity in a muchmore
potent manner than that stimulated by thrombin. These effects
are restricted to TF, as histamine enhances TNF-a- vs.
thrombin-induced VCAM-1 expression to the same extent.
Histamine induces endothelial TF expression via the H1-
receptor [13]. In line with this observation, the H1-receptor
antagonist mepyramine reduced the augmenting effect of
histamine on both TNF-a- and thrombin-induced TF expres-
sion to the level observed with TNF-a or thrombin alone.
Thus, the action of histamine on TNF-a and thrombin-induced
TF expression is mediated via the H1-receptor. Activation of
this receptor plays an important role in the pathogenesis of
vasospasm, vascular inﬂammation, and intimal thickening
after vascular injury [21–23]. Thus, our data add to the growing
evidence that histamine-induced vascular dysfunction is medi-
ated through activation of the H1-receptor.
Histamine, TNF-a, and thrombin are all known to upreg-
ulate TF expression at the transcriptional level [13,24,25].
Although histamine augmented TNF-a- and thrombin-
induced TF mRNA expression, the effect on TNF-a-induced
mRNA level was almost 2-fold higher than that on thrombin-
induced mRNA expression. Thus, the differential action of
histamine on TNF-a as compared with thrombin-induced TF
expression occurred at the transcriptional level. Post-transcrip-
tional actions contributing to this effect cannot be excluded
completely; however, such effects are unlikely because the
pattern of mRNA vs. protein expression was very similar.
Both p38 and JNK are involved in TF induction by
histamine [13], TNF-a [14,18], and thrombin [18,26]. As the
two MAPKs mediated TF induction by TNF-a and thrombin
in both the presence and the absence of histamine, we sought to
determine whether p38 or JNK could be involved in the
differential augmenting effect of histamine on TNF-a- vs.
thrombin-induced TF expression. Once histamine had activa-
ted p38, TNF-a and thrombin elicited a second activation,
which was weaker than that by TNF-a or thrombin alone;
thus, neither mediator could activate p38 a second time in a
potent manner. Consistent with this observation, inhibition of
p38 reduced TF induction by histamine plus TNF-a to a
similar degree as that by histamine plus thrombin. These data
indicate that p38 is not responsible for the differential
augmenting effect of histamine on TNF-a as compared with
thrombin-induced TF expression.
The pattern of JNK activation was not identical to that of
p38. Indeed, once histamine had activated JNK, TNF-a
elicited a second activation which was quite pronounced, while
the second activation of JNK by thrombin was markedly
weaker. This observation suggests that differential activation of
JNK may predominantly be involved in the differential
augmenting effect of histamine on TNF-a-induced as com-
pared with thrombin-induced TF expression. In order to
selectively eliminate the second wave of JNK activation, a
speciﬁc JNK inhibitor was applied 45 min after histamine
pretreatment (i.e. 15 min before stimulation with TNF-a or
thrombin). Under these conditions, JNK inhibition did not
Fig. 6. Inhibition of c-Jun NH2-terminal kinase (JNK) after pretreatment with histamine (A) Incubation of SP600125 (10
)6 mol L)1) 45 min after
stimulation with histamine has no eﬀect on histamine-induced tissue factor (TF) expression. (B) Incubation of SP600125 (10)6 mol L)1) 45 min after
pretreatment with histamine [i.e. 15 min before stimulation with tumor necrosis factor-a (TNF-a) for 5 h] reduces TNF-a-induced TF expression by 67%
(P < 0.0005). (C) Incubation of SP600125 (10)6 mol L)1) 45 min after pretreatment with histamine (i.e. 15 min before stimulation with thrombin for 5 h)
reduces thrombin-induced TF expression by 32% (P < 0.0005).
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affect TF induction by histamine alone, indicating that the
wave of activation occurring during the ﬁrst 45 min after
histamine stimulation fully accounts for the action of JNK on
histamine-induced TF expression. When cells were then
stimulated with TNF-a in the presence of the JNK inhibitor,
the augmenting effect of histamine on TF expression was
markedly reduced; however, when they were stimulated with
thrombin, the reduction was much less pronounced. This
strongly suggests that JNKplays amajor role in the differential
augmentation of TF expression by histamine.
Fig. 7. Histamine does not diﬀerentially augment tumor necrosis factor-a- (TNF-a-) and thrombin-induced vascular cell adhesion molecule-1 (VCAM-1)
expression. (A) Left panel: histamine enhances TNF-a-induced VCAM-1 expression. *P < 0.05 vs. TNF-a alone. Right panel: histamine enhances
thrombin-induced VCAM-1 expression. *P < 0.05 vs. thrombin alone. (B) TNF-a-induced VCAM-1 expression is reduced by speciﬁc inhibition of p38,
but not c-Jun NH2-terminal kinase (JNK). *P < 0.05 vs. TNF-a. (C) Thrombin-induced VCAM-1 expression is reduced by inhibition of p38, but not
JNK. *P < 0.0001, #P < 0.05 vs. thrombin. Cells were pretreated with the inhibitors for 1 h and then stimulated with TNF-a or thrombin for 5 h. (D)
VCAM-1 expression in response to histamine plus TNF-a is reduced by inhibition of p38, but not JNK. *P < 0.01 vs. TNF-a plus histamine. (E) VCAM-
1 expression to histamine plus thrombin is reduced by inhibition of p38, but not JNK. *P < 0.0001 vs. thrombin plus histamine. Cells were pretreated with
the inhibitors for 1 h, followed by histamine for 1 h and then stimulated with TNF-a or thrombin for 5 h. Blots are representative of at least three diﬀerent
experiments and normalized to alpha-tubulin expression. SB, SB203580 (10)5 mol L)1); SP, SP600125 (10)6 mol L)1).
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A key role for JNK in mediating the differential augmenting
action of histamine on TF expression is underscored by the
effect of histamine on VCAM-1 expression. In contrast to TF,
histamine enhanced TNF-a- and thrombin-induced VCAM-1
expression to a similar extent. Analysis of the signal transduc-
tion pathways revealed that p38 mediates VCAM-1 induction
in response to TNF-a and thrombin. In contrast, inhibition of
JNK did not result in a reduced VCAM-1 expression in
response to TNF-a or thrombin, both in the presence and the
absence of histamine; hence, JNK does not seem to regulate
endothelial VCAM-1 induction. Consistent with this observa-
tion, no differential augmentation of histamine was observed
with TNF-a- vs. thrombin-induced VCAM-1 expression.
Other studies found that JNK is involved in TNF-a-induced
VCAM-1 induction [27,28]: different cell culture protocols,
different TNF-a concentrations, or higher concentrations of
the JNK inhibitor in these studies may account for this
difference. Overall, there is increasing evidence that JNK plays
an important role in the development of vascular disease and
atherosclerosis; JNK is indeed involved in a variety of
proatherogenic cellular processes, including endothelial cell
activation, foam cell formation, and vascular smooth muscle
cell migration and proliferation [29].
TF is known to be involved in the pathogenesis of vascular
disease [12,30], and elevated levels of TF have been observed
in patients with hypertension, dyslipidemia, diabetic vascul-
opathy, and peripheral artery disease [12,31–34]. A patho-
genetic role of histamine in atherogenesis was highlighted by
recent studies demonstrating that histidine decarboxylase as
well as the H1-receptor are expressed in atherosclerotic
human arteries [11], and that mice deﬁcient in histidine
decarboxylase exhibit reduced intimal thickening after vas-
cular injury [10]. Invasion and activation of leukocytes are
early events in atherogenesis. Histamine and TNF-a are
released concomitantly by mast cells in vivo and exhibit a
remarkable synergy regarding endothelial cell activation;
indeed, histamine-induced endothelial interleukin production
is enhanced by TNF-a [35,36], and TNF-a-induced expres-
sion of intercellular adhesion molecule-1 and E-selectin is
potentiated by histamine [37]. Our study adds to the evidence
that histamine and TNF-a effectively interact in endothelial
activation and vascular inﬂammation and indicates that the
potent augmentation of TNF-a-induced TF expression by
histamine may play a role in the pathogenesis of thrombotic
vascular disorders such as acute coronary syndromes or
stroke [12]. Indeed, several studies observed an increase in
mast cells and histamine in coronary arteries of patients with
ischemic heart disease [9,38]. In addition, histamine elicits
potent arterial contractions [21,39], which can lead to variant
angina and have also been implicated in arterial thrombus
formation [40–42]. The enhancing effect of histamine on
TNF-a- and thrombin-induced TF expression may accelerate
thrombus formation and propagation and, eventually, vessel
occlusion.
In summary, histamine differentially augments TNF-a- vs.
thrombin-induced TF expression; a remarkable synergy of
histamine and TNF-a resulted in a strong potentiation of TF
induction, while the amine only slightly enhanced thrombin-
induced TF expression. Given the importance of vascular
inﬂammation for TF expression and thrombus formation,
these data have interesting implications for the pathogenesis of
vascular disease. Because the potentiating effect of histamine
on TNF-a- and thrombin-induced TF expression is abrogated
by H1-receptor antagonists, our ﬁndings further point to a
therapeutic potential of these drugs in the treatment of clinical
manifestations of atherosclerosis, such as acute coronary
syndromes.
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Rapamycin, but Not FK-506, Increases Endothelial Tissue
Factor Expression
Implications for Drug-Eluting Stent Design
Jan Steffel, MD*; Roberto A. Latini, MD*; Alexander Akhmedov, PhD; Dorothee Zimmermann, BSc;
Pamela Zimmerling, BSc; Thomas F. Lüscher, MD; Felix C. Tanner, MD
Background—Drugs released from stents affect the biology of vascular cells. We examined the effect of rapamycin and
FK-506 on tissue factor (TF) expression in human aortic endothelial cells (HAECs) and vascular smooth muscle cells
(HAVSMCs).
Methods and Results—Rapamycin enhanced thrombin- and tumor necrosis factor (TNF)-–induced endothelial TF
expression in a concentration-dependent manner. The maximal increase was 2.5-fold more pronounced than that by
thrombin or TNF- alone and was paralleled by a 1.4-fold higher TF surface activity compared with thrombin alone.
Rapamycin by itself increased basal TF levels by 40%. In HAVSMCs, rapamycin did not affect thrombin- or
TNF-–induced TF expression. In contrast to rapamycin, FK-506 did not enhance thrombin- or TNF-–induced
endothelial TF expression. Thrombin induced a transient dephosphorylation of the mammalian target of rapamycin
downstream target p70S6 kinase. Rapamycin completely abrogated p70S6 kinase phosphorylation, but FK-506 did not.
FK-506 antagonized the effect of rapamycin on thrombin-induced TF expression. Rapamycin did not alter the pattern
of p38, extracellular signal–regulated kinase, or c-Jun NH2-terminal kinase phosphorylation. Real-time polymerase
chain reaction analysis revealed that rapamycin had no influence on thrombin-induced TF mRNA levels for up to 2
hours but led to an additional increase after 3 and 5 hours.
Conclusions—Rapamycin, but not FK-506, enhances TF expression in HAECs but not in HAVSMCs. This effect requires
binding to FK binding protein-12, is mediated through inhibition of the mammalian target of rapamycin, and partly
occurs at the posttranscriptional level. These findings may be clinically relevant for patients receiving drug-eluting
stents, particularly when antithrombotic drugs are withdrawn or ineffective, and may open novel perspectives for the
design of such stents. (Circulation. 2005;112:2002-2011.)
Key Words: endothelium  myocardial infarction  signal transduction  stents  thrombosis
Percutaneous coronary intervention with stenting of theculprit lesion is the preferred treatment for patients with
acute coronary syndromes.1–3 Several clinical trials have
demonstrated that drug-eluting stents (DESs) are superior to
bare-metal stents (BMSs) by decreasing the restenosis rates
as well as major adverse cardiac events.4–6 Rapamycin
(sirolimus), a macrocyclic lactone, is used on DESs because
the drug inhibits proliferation and migration of vascular
smooth muscle cells (VSMCs).7 FK-506 (tacrolimus), a
macrolide immunosuppressant, is an alternative drug used
with DESs.8,9 Despite reduced restenosis rates, however, stent
thromboses have not decreased with DESs compared with
BMSs.6,10–12 Indeed, several hundred cases of in-stent throm-
bosis have been reported with rapamycin-coated stents,13 and
results from a recent multicenter registry imply that throm-
bosis rates with DESs may be higher in “real world” patients
than reported in previous clinical trials.14 The reason for the
discrepancy between reduced restenosis rates and unaltered
or even enhanced thrombosis rates with DESs compared with
BMSs is not known.6,12
Several factors are involved in the pathogenesis of in-stent
thrombosis. These include procedure-related factors such as
mechanical vessel injury or incomplete stent apposition,
patient-related factors such as vessel size or coagulation
activity, and finally, the thrombogenicity of the stent itself.15
It has not yet been explored, however, whether the drugs used
for stent coating could be involved in the development of
in-stent thrombosis.15
Tissue factor (TF), a 263-residue, membrane-bound glyco-
protein, is a key enzyme in the initiation of coagulation; it
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activates factor X (FX) by binding activated factor VII
(FVIIa), which ultimately leads to thrombin formation. Initi-
ation of coagulation is a key event in the pathogenesis of
thrombosis and acute coronary syndromes. Not surprisingly,
atheromatous plaques contain a variety of cells expressing
TF, including endothelial cells (ECs) and VSMCs. Moreover,
TF levels are elevated in the plasma and atherectomy samples
from patients with unstable angina.16 Therefore, TF seems to
be involved in the development of atherosclerosis and reste-
nosis after percutaneous coronary intervention.17–19 TF may
indeed play a major role in stent thrombosis as well. How-
ever, the effect of neither rapamycin nor FK-506 on TF
expression has been investigated so far. Moreover, the role of
the mammalian target of rapamycin (mTOR) in regulating TF
expression is also not known. Thus, the present study was
designed to investigate the influence of rapamycin and
FK-506 on TF expression in human aortic endothelial cells
(HAECs) and vascular smooth muscle cells (HAVSMCs).
Methods
Cell Culture
HAECs and HAVSMCs were cultured as described.20,21 Cells were
grown to confluence in 6-cm culture dishes and rendered quiescent
for 24 hours before stimulation with thrombin or tumor necrosis
factor (TNF)- (Sigma). Rapamycin, wortmannin (both from
Sigma), FK-506 (Alexis), and LY294002 (Cell Signaling) were
added to the dishes 60 minutes before stimulation. Cytotoxicity was
assessed with a colorimetric assay to detect lactate dehydrogenase
release according to the manufacturer’s recommendations (Roche).
Western Blot Analysis and ELISA
Protein expression was determined by Western blot analysis as
described.22,23 Cells were lysed in 50 mmol/L Tris buffer, and 30-g
samples were loaded and separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Proteins were transferred to a
polyvinylidene difluoride membrane (Millipore) by semidry transfer.
Antibody to human TF (American Diagnostica) was used at 1:2000
dilution; antibodies against the phosphorylated Thr-389 residue of
p70S6 kinase (S6K), phosphorylated p38 mitogen-activated protein
(MAP) kinase (p38), phosphorylated p44/42 MAP kinase (extracel-
lular signal–regulated kinase [ERK]), and phosphorylated c-Jun
NH2-terminal kinase (JNK; all from Cell Signaling) were used at
1:3000, 1:1000, 1:5000, and 1:1000 dilution, respectively. Antibod-
ies against total S6K, total p38, total ERK, and total JNK (all from
Cell Signaling) were used at 1:3000, 1:2000, 1:10 000, and 1:1000
dilution, respectively. All blots were normalized to -tubulin (aT)
expression (1:20 000 dilution, Sigma). Endothelial TF expression
was also measured with a commercially available ELISA (American
Diagnostica) according to the supplier’s recommendations.
Real-Time PCR Analysis
RNA was extracted and converted to cDNA as described.22 Real-
time polymerase chain reaction (PCR) was performed in an
MX3000P PCR cycler (Stratagene). All PCR experiments were
performed with the SYBR Green JumpStart kit (Sigma). Each
reaction (25 L) contained 2 L cDNA, 1 pmol of each primer, 0.25
L of internal reference dye, and 12.5 L of JumpStart Taq
ReadyMix (containing buffer, dNTPs, stabilizers, SYBR Green, Taq
polymerase, and JumpStart Taq antibody). Primers for human TF
were used as described.22,24 Expression of the ribosomal protein L28
(L28) mRNA was used as a loading control; primers for human L28
were designed as follows: sense primer, 5-GCATCTGC-
AATGGATGGT-3 and antisense primer, 5-TGTTCTTGCG-
GATCATGTGT-3. The amplification program consisted of 1 cycle
at 95°C for 10 minutes; followed by 40 cycles with a denaturing
phase at 95°C for 30 seconds, an annealing phase at 60°C for 1
minute, and an elongation phase at 72°C for 1 minute. A melting
curve analysis was performed after amplification to verify the
homogeneity of the amplicon. For verification of amplicon size, PCR
products were analyzed on an ethidium bromide–stained 1% agarose
gel. In each real-time PCR run for TF and L28, a calibration curve
generated from serial dilutions of a known TF and L28 standard,
respectively, was included, and for each sample, the target values
were corrected by those for L28.
TF Surface Activity
A colorimetric assay (American Diagnostica) was used to analyze TF
surface activity according to the manufacturer’s recommendations,
with some modifications as described.22,25 Cells were grown in
6-well plates; after stimulation, cells were washed twice with
phosphate-buffered saline and incubated with human FVIIa and FX
at 37°C, resulting in the formation of a TF/FVIIa complex at the cell
surface. The TF/FVIIa complex converted human FX to FXa, which
was subsequently measured by its ability to cleave a chromogenic
substrate. Different concentrations of lipidated human TF were used
as positive controls to confirm that the obtained results were in the
linear range of detection (data not shown).
Proliferation
To examine the effect of rapamycin and FK-506 on EC proliferation,
HAECs were seeded on 6-cm dishes at 7000 cells/cm2. After 24
hours, when cells had reached 50% confluence, they were serum-
starved for 24 hours before incubation with rapamycin (107 mol/L),
FK-506 (107 mol/L), or carrier (0.1% dimethyl sulfoxide) in
endothelial basal medium (EBM, Clonetics) containing 10% fetal
calf serum (FCS). At the indicated times, cells were gently
trypsinized and counted in a hemacytometer. Each analysis was
performed in duplicate; results are representative of 3 independent
experiments.
Apoptosis
To assess induction of apoptosis by rapamycin and FK-506, cells
were cultured in chamber slides (Nunc) at 20 000 cells/well for 24
hours before serum-starvation for 24 hours. Cells were then incu-
bated in EBM with 10% FCS containing rapamycin (107 mol/L),
FK-506 (107 mol/L), or carrier (0.1% dimethyl sulfoxide). At the
indicated times, cells were fixed with 4% paraformaldehyde and
processed for terminal deoxynucleotidyl nick end-labeling (TUNEL)
staining with a commercially available kit (Roche) according to the
manufacturer’s recommendations. Afterward, cells were counter-
stained with 4,6 diamidino-2-phenylindole (DAPI; Vector) and
counted under a fluorescence microscope. Two hundred cells per
time point and condition were counted, and the number of TUNEL-
positive cells was assessed.
Statistics
Data are presented as meanSEM. Unpaired Student t test was used for
statistical analysis. A probability value 0.05 was considered
significant.
Results
Rapamycin Enhances TF Expression in HAECs
but Not HAVSMCs
Stimulation of HAECs with thrombin (1 U/mL) induced TF
expression 23-fold as assessed by Western blotting analysis
(Figure 1A). Incubation with rapamycin (108 to 107 mol/L)
before stimulation with thrombin resulted in a concentration-
dependent enhancement of TF expression (Figure 1A). The
maximal increase was observed after 5 hours and was
2.3-fold compared with stimulation with thrombin alone and
51-fold compared with the basal level. Similarly, rapamycin
(108 to 107 mol/L) enhanced TF expression in response to
TNF- (5 ng/mL); this increase was 2.5-fold, resulting in a
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35-fold induction compared with the basal level (Figure 1B).
ECs express TF only at very low levels under basal conditions,26
and stimulation of HAECs with rapamycin alone increased basal
TF expression by 40%, as assessed by Western blotting analysis
(Figure 1C), or 25% as assessed by ELISA (Figure 1D).
Expression of TF was 451 pg per 500 000 cells for control,
573 pg per 500000 cells for rapamycin (107 mol/L) alone,
46829 pg per 500 000 cells for thrombin stimulation, and
70230 pg/500 000 cells for thrombin stimulation in the pres-
ence of rapamycin (Figure 1D). The rapamycin-enhanced in-
crease in thrombin-induced TF expression was paralleled by an
increase of TF surface activity, which reached 1.4 times the level
induced by thrombin alone (Figure 1E).
Similar to HAECs, thrombin (1 U/mL) and TNF- (5
ng/mL) induced TF expression in HAVSMCs. In contrast to
HAECs, however, rapamycin did not affect TF expression in
response to either mediator in this cell type (Figure 2A and
2B). No cytotoxic effect of rapamycin was observed for any
of the concentrations used (n4, PNS; data not shown).
FK-506 Does Not Affect TF Expression
Incubation with FK-506 (108 to 107 mol/L) before stimu-
lation with thrombin (1 U/mL, Figure 3A) or TNF- (5
ng/mL, Figure 3B) did not alter TF expression. No cytotoxic
effect of FK-506 was observed for any of the concentrations
used (n4, PNS; data not shown).
Figure 1. Rapamycin enhances TF
expression in HAECs. A, Rapamycin
enhances thrombin-induced TF expres-
sion in a concentration-dependent man-
ner. Values are given as a percentage of
stimulation with thrombin alone.
*P0.0001, ** P0.001 vs thrombin
alone. B, Rapamycin enhances TNF-–
induced TF expression in a
concentration-dependent manner. Values
are given as a percentage of stimulation
with TNF- alone. *P0.02, ** P0.01 vs
TNF- alone. C, Rapamycin increases
basal TF expression. Values are given as
a percentage of unstimulated control.
*P0.01 vs unstimulated control. Values
are representative of at least 3 different
experiments; all blots were normalized to
aT expression. D, TF ELISA confirms that
rapamycin increases both basal (*P0.05
vs unstimulated control) and thrombin-
induced (**P0.01 vs thrombin alone) TF
expression. E, Rapamycin enhances
thrombin-induced TF surface activity in a
concentration-dependent manner. Values
are given as a percentage of stimulation
with thrombin alone. *P0.01 vs throm-
bin alone.
Figure 2. Rapamycin does not affect TF
expression in HAVSMCs. Rapamycin
does not affect thrombin- (A) or TNF-–
(B) induced TF expression in HAVSMCs.
Values are given as a percentage of
stimulation with thrombin (1 U/mL) or
TNF- (5 ng/mL) alone. Blots are repre-
sentative of at least 4 different experi-
ments; all blots were normalized to aT
expression.
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Rapamycin Enhances TF Expression by Inhibiting
mTOR Activity
Phosphorylation of S6K, a downstream target of the mTOR,
is frequently used to assess mTOR inhibition by rapamy-
cin.27,28 When stimulated with thrombin (1 U/mL), S6K
phosphorylation was transiently decreased after 30 minutes to
a minimum of 19% of the basal level (Figure 4A, left).
Rapamycin (107 mol/L) completely abrogated S6K phos-
phorylation, in both the presence and absence of thrombin
(Figure 4A, right). Similarly, inhibition of phosphatidyl
inositol 3-kinase with LY294002 or wortmannin almost
completely abrogated S6K phosphorylation, again indepen-
dent of thrombin stimulation (Figure 4C). In contrast, FK-506
(107 mol/L) did not affect phosphorylation of S6K in either
the presence or absence of thrombin (Figure 4B).
Rapamycin Enhances TF Expression by Binding
to FKBP-12
Rapamycin and FK-506 bind to the same intracellular recep-
tor, FK binding protein-12 (FKBP-12). When HAECs were
treated with increasing concentrations of FK-506 for 30
minutes before incubation with rapamycin, FK-506 reduced
the effect of rapamycin on thrombin-induced TF expression
(Figure 5). Indeed, when incubated with the highest concen-
tration of FK-506 (107 mol/L), the increase in TF expression
elicited by rapamycin with respect to stimulation with throm-
bin alone was reduced by 41% (P0.05).
Effect of Rapamycin on Thrombin-Induced TF
mRNA Levels
Real-time PCR revealed that thrombin induced TF mRNA
expression in a time-dependent manner (Figure 6A). Rapa-
mycin did not alter thrombin-induced mRNA expression
compared with stimulation by thrombin alone after 0.5, 1, and
2 hours. However, after 3 and 5 hours of stimulation,
rapamycin significantly augmented thrombin-induced TF
mRNA levels (Figure 6A and 6B). Rapamycin significantly
increased thrombin-induced TF protein expression after 3, 5,
and 7 hours compared with stimulation by thrombin alone
(Figure 6C).
Rapamycin did not affect the pattern of MAP kinase
activation observed after thrombin stimulation. Indeed, phos-
phorylation of p38 (Figure 7A), ERK (Figure 7B), and JNK
(Figure 7C) remained unaltered after pretreatment with rapa-
mycin compared with stimulation by thrombin alone.
Rapamycin, but Not FK-506, Inhibits
EC Proliferation
EC proliferation was induced by incubation with EBM
containing 10% FCS (Figure 8A, control). Rapamycin (107
mol/L) prevented FCS-induced EC proliferation. In contrast,
FK-506 (107 mol/L) did not significantly inhibit EC prolif-
eration (Figure 8A).
TUNEL staining was used to examine whether rapamycin
(107 mol/L) or FK-506 (107 mol/L) induced apoptosis in
HAECs (Figure 8B). Representative sections are shown.
After 24 hours, TUNEL-positive cells accounted for
5.30.7% of cells in the control group, 4.71.7% for
rapamycin (PNS versus control), and 4.81.5% for FK-
506 (PNS versus control). After 48 hours, 4.21.7% of
control cells, 3.50.6% of rapamycin-treated cells (PNS
versus control), and 4.62.3% of FK-506-treated cells
(PNS versus control) were TUNEL-positive. Cells incu-
bated with H2O2 (1 mmol/L) for 6 hours as well as serum
withdrawal for 48 hours served as positive controls and
resulted in a significant increase in apoptotic cells (data not
shown). Thus, neither rapamycin (107 mol/L) nor FK-506
(107 mol/L) led to an increase in apoptotic cells compared
with control conditions.
Discussion
This study demonstrates that rapamycin enhances endothelial
TF expression in response to thrombin and TNF-. The
concentrations of rapamycin occurring in vivo compare well
with those used in our study, as maximal systemic concen-
trations of rapamycin after deployment of 2 sirolimus-eluting
Figure 3. FK-506 does not affect TF
expression in HAECs. FK-506 does not
affect thrombin- (A) or TNF-– (B)
induced TF expression in HAECs. Values
are presented as a percentage of stimu-
lation with thrombin (1 U/mL) or TNF- (5
ng/mL) alone. Blots are representative of
at least 3 different experiments; all blots
were normalized to aT expression.
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stents are reported to be 1 ng/mL (1.15109 mol/L)29;
moreover, local concentrations, though difficult to assess, are
likely to be significantly higher, partly because of rapamy-
cin’s lipophilic properties, leading to accumulation of the
drug in the vessel wall.11,30–32 Thus, the concentrations used
in our study may be relevant for patients treated with DESs.
Reendothelialization is initiated soon after vascular injury;
indeed, it has been observed to begin as early as 2 days after
balloon dilation in animal models.33–35 In humans, partial
reendothelialization has been documented 3 weeks after stent
deployment.35–37 Sirolimus-eluting stents are designed in
such a way that 80% of the rapamycin has eluted by 30
Figure 4. Rapamycin inhibits endothelial
mTOR activity. A, Thrombin leads to a
transient, time-dependent inhibition of
S6K phosphorylation (left). Rapamycin
(right) completely abrogates S6K phos-
phorylation in both the presence and
absence of thrombin. Total levels of S6K
remain unchanged. Values are presented
as phosphorylated (Pho) S6K/total (Tot)
S6K. *P0.0001 vs unstimulated condi-
tions. B, FK-506 affects neither basal
phosphorylation levels nor thrombin-
induced inhibition of S6K phosphoryla-
tion. Values are presented as phosphory-
lated S6K (Pho)/total (Tot) S6K. C,
LY294002 (5106 mol/L, left) and wort-
mannin (107 mol/L, right) almost com-
pletely abrogate S6K phosphorylation
(Pho). Total (Tot) levels of S6K remain
unchanged.
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days.4,5 Furthermore, rapamycin easily penetrates cell walls
owing to its lipophilic properties, leading to chronic retention
of the drug in arterial tissue.30–32 Thus, the time course of
reendothelialization versus the kinetics of rapamycin release
suggests that rapamycin-enhanced endothelial TF expression
may be involved in the pathogenesis of in-stent thrombosis.
In addition, inhibition of endothelial proliferation by rapamy-
cin indicates that rapamycin delays reendothelialization,
which may increase stent thrombogenicity even further.
Several hundred cases of acute and subacute in-stent
thrombosis have been observed after deployment of
rapamycin-eluting stents.13 In addition and in contrast to
BMSs, late thrombosis has been reported after withdrawal of
antithrombotic drugs with DESs.10 Most of these data origi-
nated from case reports or were collected in controlled
clinical trials. Recent results from a large-scale, multicenter
registry, however, indicate that in-stent thrombosis is likely
underestimated under these circumstances and that it may
occur at substantially higher rates in real world patients.14 The
pathogenesis of in-stent thrombosis has not yet been fully
explored15; moreover, it is not known whether the pathogenic
events leading to thromboses of DESs are similar to those of
BMSs. Enhanced TF expression in the presence of rapamycin
may indeed favor the development of in-stent thrombosis
after deployment of sirolimus-eluting stents, particularly
when clopidogrel is withdrawn or ineffective because of drug
resistance.38 FK-506, which neither affects endothelial TF
expression nor inhibits EC proliferation, may provide a more
favorable environment for reducing thromboses of DESs. To
assess the implications of these findings in vivo, however,
further studies are needed to examine the degree as well as the
spatiotemporal pattern of TF expression in the arterial wall
after deployment of DESs.
Platelet activation is a crucial event in the pathogenesis of
thrombus formation. Consequently, the use of platelet recep-
tor blockers such as clopidogrel have greatly reduced the
incidence of stent thromboses, whereas withdrawal of anti-
platelet therapy favors thrombus formation.10,14 Moreover,
clopidogrel inhibits the release of TF from aggregating
platelets,39 which is of particular interest, as platelet aggre-
gation and secretion are increased in human platelets treated
with rapamycin.40 Thus, effective antiplatelet therapy may
account for the fact that thrombosis rates of sirolimus-eluting
stents are not clearly higher than those of BMSs.
TF induction after deployment of rapamycin-eluting stents
may also have a prothrombotic effect on ECs distal to the
stented site. Indeed, remote effects of rapamycin have been
demonstrated, with pronounced endothelial dysfunction in
coronary arteries distal to sirolimus-eluting stents compared
with BMSs.41 Thus, in addition to the effect on ECs within
the stented region, rapamycin may also increase TF expres-
sion in ECs in the distal coronary vasculature. Such an effect
may also contribute to the no-reflow phenomenon after stent
deployment.
Rapamycin did not enhance thrombin- or TNF-–driven
TF expression in HAVSMCs, indicating that rapamycin does
not constitute an additional thrombogenic signal to the
VSMC layer. Indeed, a much higher incidence of acute and
subacute stent thromboses would be expected if rapamycin
induced TF expression in VSMCs. Although the rapamycin-
induced increase in endothelial TF expression may favor
neointima formation via the release of growth factors from
aggregating platelets, the inhibitory effect of rapamycin on
the proliferation and migration of VSMC is very likely to
protect the vessel from such effects.7 Consistent with this
interpretation, sirolimus-eluting stents reduce neointima for-
mation despite inducing a procoagulative state owing to
enhanced endothelial TF expression.
Both thrombin, a coagulation factor, and TNF-, an
inflammatory cytokine, are classic inducers of TF expression
in vascular cells. Thrombin induced TF expression 27-fold
when examined by Western blotting analysis and 10.3-fold by
ELISA; similarly, rapamycin enhanced thrombin-induced TF
expression by 2.3-fold in Western blot analysis and 1.5-fold
by ELISA. This difference may be due to a different sensi-
tivity and/or specificity of the 2 assays. In our study,
rapamycin enhanced TF expression in response to both
thrombin and TNF-; it may thus upregulate TF expression in
a prothrombotic as well as an inflammatory environment,
both of which are encountered in the coronary vasculature
after stent deployment.
Biologically active TF is located at the cell surface, and
rapamycin-enhanced TF protein expression was indeed paral-
leled by an increase in TF surface activity. The increase in
activity was not as pronounced as that of protein expression;
this discrepancy has also been observed in response to
thrombin alone.42 The distribution of TF in several cellular
compartments and/or the expression of encrypted TF might
account for this difference.43
The inhibitory role of phosphatidyl inositol 3-kinase on TF
expression is established, as its inhibition enhances TF
expression in response to thrombin.42,44 The mTOR is a
downstream target of phosphatidyl inositol 3-kinase.28 Bind-
ing of rapamycin to its intracellular receptor FKBP-12 leads
Figure 5. FK-506 antagonizes rapamycin-induced TF expres-
sion. Preincubation with FK-506 reduces rapamycin-enhanced
TF expression. Values are presented as a percentage of stimula-
tion with thrombin (1 U/mL) and rapamycin (107 mol/L).
*P0.05 and **P0.02, compared with thrombin and rapamycin
(107 mol/L). Blots are representative of at least 3 different
experiments; all blots were normalized to aT expression.
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to formation of the rapamycin–FKBP-12 complex, which in
turn inhibits mTOR activity. Phosphorylation of the down-
stream target of mTOR, S6K, is routinely used as a readout
for the inhibitory effect of rapamycin on mTOR27,28; indeed,
mTOR-dependent phosphorylation of the Thr-389 residue of
S6K is necessary for its activity.27 In the present study, we
have shown that stimulation with thrombin leads to a tran-
sient inhibition of S6K phosphorylation. Rapamycin as well
as the phosphatidyl inositol 3-kinase inhibitors wortmannin
and LY294002 abrogated S6K phosphorylation in both the
presence and absence of thrombin. Because thrombin stimu-
lation as well as preincubation with rapamycin led to inhibi-
tion of this pathway, resulting in disinhibition of TF expres-
sion, these observations are consistent with the interpretation
that mTOR plays an inhibitory role in TF expression.
FK-506 competitively binds to the same intracellular re-
ceptor as rapamycin, ie, FKBP-12.45 In contrast to rapamycin,
however, the FK-506–FKBP-12 complex inhibits the phos-
phatase calcineurin and has no effect on mTOR activity.46
Consistently, FK-506 did not alter thrombin- or TNF-–
induced TF expression. To assess the specificity of our
observations, we coincubated FK-506 and rapamycin before
thrombin stimulation. The enhancing effect of rapamycin on
thrombin-induced TF expression could indeed be reduced by
FK-506. These findings indicate that binding of rapamycin to
FKBP-12 is necessary for inhibition of mTOR activity and
enhancement of TF expression.
TF expression in response to a variety of stimuli is
mediated by MAP kinase activation, leading to increased
transcription.22,24,42 Indeed, thrombin induced an increase in
p38, ERK, and JNK phosphorylation as well as an increase in
TF transcription. However, rapamycin did not alter the
pattern of thrombin-induced p38, ERK, and JNK activation.
Figure 6. Effect of rapamycin on TF mRNA induc-
tion. A, Real-time PCR demonstrates a time-
dependent induction of TF mRNA in response to
thrombin. Rapamycin does not alter this pattern of
induction after stimulation for 0.5, 1, and 2 hours.
Values are given as a percentage of stimulation
with thrombin alone for 2 hours. B, Analysis of
CT values comparing the effect of rapamycin on
thrombin-induced mRNA levels for every time point
reveals that rapamycin significantly increases
thrombin-induced TF mRNA after stimulation for 3
and 5 hours. *P0.0005, **P0.005. All values are
representative of 4 different experiments and were
normalized to L28 mRNA expression. C, Rapamy-
cin enhances thrombin-induced TF protein expres-
sion in a time-dependent manner. Values are given
as a percentage of stimulation with thrombin alone
for 3 hours. *P0.0001, **P0.01 vs thrombin
alone. Values are representative of at least 3 differ-
ent experiments. All blots were normalized to aT
expression.
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Consistent with this observation, thrombin-induced mRNA
levels were unchanged by rapamycin for up to 2 hours after
stimulation. However, after 3 and 5 hours of thrombin
stimulation, rapamycin increased mRNA levels compared
with stimulation by thrombin alone. Taken together, these
data imply that the enhancing effect of rapamycin on
thrombin-induced TF expression initially occurs at the post-
transcriptional level and hence, is independent of MAP kinase
Figure 7. Rapamycin does not affect MAP kinase activation. Stimulation with thrombin leads to phosphorylation (Pho) of the MAP
kinases p38 (A), ERK (B), and JNK (C). Rapamycin does not alter this pattern of MAP kinase activation. Total (Tot) levels of p38, ERK,
and JNK remain unchanged. Blots are representative of at least 3 different experiments.
Figure 8. Rapamycin, but not FK-506, inhibits EC proliferation. A, Rapamycin completely inhibits EC proliferation induced by 10% FCS;
in contrast, FK-506 does not significantly affect EC proliferation. *P0.05 vs control; **P0.005 vs control; and **P0.002 vs FK-506.
Three different experiments were performed in duplicate for each experimental condition. B, There was no increase in TUNEL-positive
cells after incubation with rapamycin or FK-506 for 24 and 48 hours. Slides show representative TUNEL-positive cells with the corre-
sponding DAPI staining after 24 hours of incubation with carrier (left), rapamycin (middle), and FK-506 (right).
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activation, although a transcriptional effect of rapamycin
cannot be ruled out at later time points. Indeed, mTOR is
known to exert posttranscriptional effects, and TF expression
can be regulated at both the transcriptional and posttranscrip-
tional level.47,48
In summary, our study reveals that rapamycin, but not
FK-506, enhances endothelial TF expression and reduces
HAEC proliferation. These effects may favor the develop-
ment of thrombus formation after deployment of sirolimus-
eluting stents, particularly when antithrombotic drugs are
withdrawn or ineffective, and may have interesting implica-
tions for the design of DESs.
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Paclitaxel Enhances Thrombin-Induced Endothelial Tissue
Factor Expression via c-Jun Terminal NH2
Kinase Activation
Barbara E. Sta¨hli,* Giovanni G. Camici,* Jan Steffel, Alexander Akhmedov, Kushiar Shoojati,
Michelle Graber, Thomas F. Lu¨scher, Felix C. Tanner
Abstract—Paclitaxel is used on drug-eluting stents because it inhibits proliferation of vascular cells. Stent thrombosis
remains a concern with this compound, particularly with higher dosages. This study investigates the effect of paclitaxel
on tissue factor (TF) expression in human endothelial cells. Paclitaxel enhanced thrombin-induced endothelial TF
protein expression in a concentration- and time-dependent manner. A concentration of 105 mol/L elicited a 2.1-fold
increase in TF protein and a 1.6-fold increase in TF surface activity. The effect was similar after a 1 hour as compared
with a 25-hour pretreatment period. Real-time polymerase chain reaction revealed that paclitaxel increased thrombin-
induced TF mRNA expression. Paclitaxel potently activated c-Jun terminal NH2 kinase (JNK) as compared with
thrombin alone, whereas the thrombin-mediated phosphorylation of p38 and extracellular signal-regulated kinase
remained unaffected. Similar to paclitaxel, docetaxel enhanced both TF expression and JNK activation as compared with
thrombin alone. The JNK inhibitor SP600125 reduced thrombin-induced TF expression by 35%. Moreover, SP600125
blunted the effect of paclitaxel and docetaxel on thrombin-induced TF expression. Paclitaxel increases endothelial TF
expression via its stabilizing effect on microtubules and selective activation of JNK. This observation provides novel
insights into the pathogenesis of thrombus formation after paclitaxel-eluting stent deployment and may have an impact
on drug-eluting stent design. (Circ Res. 2006;99:0-0.)
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Percutaneous intervention is common practice for treatingacute coronary syndromes.1,2 Drug-eluting stents (DES),
which are coated with antiproliferative agents, improve the
outcome after coronary artery stenting.3 Paclitaxel, a
microtubule-stabilizing drug eliciting cell cycle arrest in
G2/M phase, is used on DES because it reduces vascular
smooth muscle cell proliferation and migration.4 Several
randomized clinical trials have demonstrated that paclitaxel-
eluting stents decrease intimal hyperplasia and restenosis,
leading to reduced rates of major adverse cardiac events as
compared with bare-metal stents (BMS).3,5–7 In contrast, the
use of DES has not reduced the occurrence of stent throm-
bosis as compared with BMS.3,5,7–9 Acute, subacute, and late
in-stent thromboses have been observed in patients treated
with paclitaxel-eluting stents, particularly following cessation
of clopidogrel therapy.8,10–12 Moreover, the SCORE trial,
which analyzed the effect of a stent releasing higher pacli-
taxel concentrations than the TAXUS stent, had to be termi-
nated because of increased rates of in-stent thrombosis.13
Although in-stent thrombosis after TAXUS stent implanta-
tion is less frequent, its rates may still be higher in “real
world” patients than those reported in clinical trials.7,10,11 In
addition, if in-stent thrombosis occurs, it is associated with
high morbidity and mortality.14
Tissue factor (TF) is a 47-kDa transmembrane glycopro-
tein-binding factor VIIa (FVIIa) and, in turn, activates FIX
and FX15,16; thereby, the TF/FVIIa complex is the principal
initiator of coagulation. It is well documented that TF is
highly expressed in atherosclerotic plaques and that initiation
of coagulation is a key event in the pathogenesis of acute
coronary syndromes.17 TF antigen and activity are indeed
higher in plaques from patients with unstable angina or
myocardial infarction than in those from patients with stable
angina,17,18 and increased TF plasma levels are found in
unstable angina and acute myocardial infarction.17,19,20 Given
the important role of TF in acute coronary syndromes, it may
be involved in the pathogenesis of in-stent thrombosis as
well.
Rapamycin, another drug used with DES, does indeed
enhance endothelial TF expression.21 The effect of paclitaxel
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on TF expression, however, is not known. This study was
therefore designed to examine the effect of paclitaxel on TF
expression in human endothelial cells.
Materials and Methods
Cell Culture and Morphology
Human aortic endothelial cells (HAECs) were purchased from
Clonetics and cultured as described.22 Cells were grown to conflu-
ence in 3-cm culture dishes, rendered quiescent for 24 hours in
medium containing 0.5% FCS, and then stimulated with 1 U/mL
thrombin (Sigma). Paclitaxel (Sigma and Alexis) was added to the
dishes 1 hour before stimulation. To assess cytotoxicity, a colori-
metric assay for detection of lactate dehydrogenase (LDH) was used
according to the recommendations of the manufacturer (Roche). Cell
morphology was evaluated by phase–contrast microscopy (Leitz
DM IRB) at 50 magnification and photographed (Olympus DP 50)
without fixation.
Western Blot Analysis
Protein expression was determined by Western blot analysis as
described.23 Cells were lysed in 50 mmol/L Tris buffer, 25 g was
loaded per lane, and 10% SDS-PAGE was performed under reducing
conditions. Resolved proteins were transferred to polyvinylidene
fluoride (PVDF) membranes (Millipore) by semidry transfer. The
antibody against human TF (American Diagnostica) was used at
1:2000 dilution; antibodies against phosphorylated p38 mitogen-ac-
tivated protein (MAP) kinase (p38), phosphorylated p44/42 MAP
kinase (extracellular signal-regulated kinase [ERK]), and phosphor-
ylated c-jun terminal NH2 kinase (JNK) (all from Cell Signaling)
were used at 1:1000, 1:5000, and 1:1000 dilution, respectively.
Antibodies against total p38, total ERK, and total JNK (all from Cell
Signaling) were used at 1:2000, 1:5000, and 1:1000 dilution,
respectively. The antibody against IkB- (Santa Cruz) was applied at
1:1000 dilution. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression was used to ensure equal protein loading at an
antibody (Chemicon) dilution of 1:20000. Proteins were detected
with a horseradish peroxidase–linked secondary antibody
(Amersham).
Real-Time PCR
Total RNA was extracted with 1 mL TRIzol Reagent (Invitrogen)
according to the recommendations of the manufacturer. Conver-
sion of total cellular RNA to cDNA was performed with Moloney
murine leukemia virus reverse transcriptase and random hexamer
primers (Amersham Bioscience) in a final volume of 33 L using
4 g of RNA. Real-time PCR amplification was performed in an
MX3000P PCR cycler (Stratagene) using the SYBR Green
JumpStart kit (Sigma) in 25 L of final reaction volume contain-
ing 2 L of cDNA, 10 pmol of each primer, 0.25 L of internal
reference dye, and 12.5 L of JumpStart Taq ReadyMix (buffer,
dNTP, stabilizers, SYBR Green, Taq polymerase, and JumpStart
Taq antibody).24 The total cDNA pool obtained served as tem-
plate for subsequent PCR amplification with TF (F3)-specific
primers (sense primer: 5-TCCCCAGAGTTCACACCTTACC-
3; bases 508 to 529 of F3 cDNA; National Center for Biotech-
nology Information [NCBI] no. NM 001993; antisense primer:
5-TGACCACAAATACCACAGCTCC-3; bases 892 to 913 of
F3 cDNA; NCBI no. NM 001993) using the following cycling
parameters: 95° for 10 minutes for 1 cycle; 95° for 30 seconds,
60° for 1 minute, 72° for 1 minute, for a total of 40 cycles. A
melting curve analysis was performed after amplification to
verify the accuracy of the amplicon. L28 primers served as
loading control. Products were separated by electrophoresis on a
1.6% agarose gel and visualized with ethidium bromide.
TF Surface Activity
TF surface activity was analyzed with a colorimetric assay (Ameri-
can Diagnostica) according to the recommendations of the manufac-
turer with some modifications as described.25 Cells were grown to
confluence in 12-well plates, stimulated with thrombin, washed
twice with PBS, and incubated with human FVIIa and FX at 37°.
This allowed the formation of a TF/FVIIa complex at the cell
surface. This complex converted human FX to FXa, which was
measured by its ability to cleave a chromogenic substrate. A standard
curve was established with lipidated human TF to ensure that the
results were in the linear range of detection (data not shown).
Figure 1. Paclitaxel enhances thrombin-induced TF protein
expression. A, Paclitaxel enhances thrombin-induced TF protein
expression in a concentration-dependent manner (n6;
*P0.0005 vs thrombin alone). Values are given as percentage
of TF expression in response to 5 hours of thrombin stimulation.
Blots are normalized to GAPDH expression. B, Similar effect of
paclitaxel on thrombin-induced TF protein expression after 1
hour and 25 hours of pretreatment (n4; *P0.005 vs thrombin
alone, PNS for 1 vs 25 hours). C, Paclitaxel enhances
thrombin-induced TF surface activity (n3; *P0.005 vs throm-
bin alone). Values are given as percentage of TF surface activity
in response to 5 hours of thrombin stimulation.
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Statistical Analysis
Data are reported as meanSEM. Unpaired Student’s t test was
performed for statistical analysis. A probability value of 0.05 was
considered to indicate a significant difference.
Results
Paclitaxel Enhances TF Protein Expression and
Surface Activity
HAECs were stimulated with thrombin (1 U/mL) for 5 hours
in the presence or absence of paclitaxel (109 to 105 mol/L).
Thrombin induced a 20-fold increase in TF expression as
compared with baseline (n7; P0.0001; Figure 1A). Pre-
treatment with paclitaxel enhanced thrombin-induced TF
expression in a concentration-dependent manner; a maximal
effect occurred at 105 mol/L and resulted in a 2.1-fold
induction as compared with thrombin alone, corresponding to
a 43.3-fold induction as compared with baseline (n6;
P0.0005; Figure 1A). The effect of paclitaxel was similar
after a 1 hour as compared with a 25 hour pretreatment period
(n4; PNS for 1 versus 25 hours; Figure 1B). The effect of
paclitaxel was first observed after 3 hours and elicited a
significant increase in thrombin-induced TF expression after
5 and 7 hours (n4; P0.05; Figure 3B). In another
time-course analysis, thrombin-induced TF expression was
maximal after 6 hours of stimulation and decreased to 50%
after 12 hours, 32% after 18 hours, and 27% after 24 hours;
paclitaxel significantly enhanced thrombin-induced TF ex-
pression by 2.2-fold after 6 hours (n4; P0.05) and by
1.4-fold after 12 hours (n4; P0.05), although its effect did
not reach statistical significance after 18 and 24 hours (n4;
PNS) (data not shown). Consistent with these observations,
paclitaxel enhanced thrombin-induced TF surface activity by
56% (n3; P0.005; Figure 1C). Paclitaxel alone did not
affect basal TF expression (n7; PNS; Figure 1A). Pacli-
taxel did not affect endothelial cell morphology (Figure 2A)
nor LDH release (Figure 2B) at any concentration used (n5;
PNS).
Paclitaxel Enhances TF mRNA Expression
Real-time PCR revealed that thrombin (1 U/mL) induced TF
mRNA expression with a maximal effect occurring after 2
hours. Pretreatment with paclitaxel (105 mol/L) enhanced
thrombin-induced TF mRNA expression by 1.6-fold after 1
hour (n5; P0.05; Figure 3A), by 1.5-fold after 2 hours
(n5; P0.09; Figure 3A), and by 1.7-fold after 3 hours
(n5; P0.21; Figure 3A).
Paclitaxel Selectively Activates JNK
Thrombin induced a transient phosphorylation of the MAP
kinases p38, ERK, and JNK. Maximal activation of JNK was
observed after 60 minutes, whereas that of p38 and ERK
occurred after 5 minutes.21 Paclitaxel significantly increased
JNK phosphorylation after 15, 30, and 60 minutes by 3.7-,
3.2-, and 2.0-fold, respectively, as compared with thrombin
alone (n4; P0.05 for each time point; Figure 4A). Phos-
phorylation of p38 was slightly prolonged by paclitaxel after
15 minutes of stimulation (n4; P0.005; Figure 4B),
whereas all of the other time points remained unaltered (n4;
PNS; Figure 4B). Phosphorylation of ERK was not affected
by paclitaxel, except for a slight decrease at the 5-minute time
point (n4; P0.01; Figure 4C). Neither thrombin nor
paclitaxel altered total expression of MAP kinases.
Thrombin-induced IkB- degradation was not affected by
pretreatment with paclitaxel (n3; PNS; data not shown).
Paclitaxel and Docetaxel Exert Similar Effects on
Both TF and JNK
HAECs were stimulated with thrombin (1 U/mL) for 5 hours
in the presence or absence of paclitaxel or docetaxel (both at
106 and 105 mol/L). Similar to paclitaxel, docetaxel en-
hanced thrombin-induced TF expression by 2.2-fold as com-
pared with thrombin alone (n4; P0.05 for thrombin plus
paclitaxel versus thrombin alone; P0.005 for thrombin
plus docetaxel versus thrombin alone; PNS for thrombin
plus paclitaxel versus thrombin plus docetaxel; Figure 5A).
Docetaxel did not affect endothelial cell morphology nor
LDH release at any concentration used (n3; PNS; data
not shown).
Similar to paclitaxel, docetaxel enhanced JNK phosphory-
lation as compared with thrombin alone. The increase in JNK
activation after 2 hours of thrombin stimulation was 3.2-fold
for paclitaxel and 2.2-fold for docetaxel (n4; P0.0001 for
thrombin plus paclitaxel versus thrombin alone; P0.05
for thrombin plus docetaxel versus thrombin alone; PNS
for thrombin plus paclitaxel versus thrombin plus docetaxel;
Figure 5B).
JNK Mediates the Effect of Paclitaxel and
Docetaxel on TF
HAECs were pretreated with SP600125, a specific inhibitor
of JNK, 90 minutes before stimulation with thrombin (1
U/mL). SP600125 (106 mol/L) reduced thrombin-induced
TF expression by 35% (n3; P0.01; Figure 5C). Moreover,
SP600125 reduced the effect of paclitaxel on thrombin-
induced TF expression by 110% and that of docetaxel by
105%, respectively (n4; P0.0001 for paclitaxel versus
paclitaxel plus SP600125; P0.05 for docetaxel versus
docetaxel plus SP600125; Figure 5D). Hence, inhibition of
JNK by SP600125 blunted the effect of paclitaxel and
docetaxel on thrombin-induced TF expression (n4; PNS
Figure 2. Lack of toxicity of paclitaxel. A,
Morphology of HAECs after 5 hours of
thrombin stimulation is similar without
(left) and with (right) paclitaxel (105 mol/
L). Magnification, 50. B, LDH release
reveals no cytotoxic effect of paclitaxel
on HAECs at any concentration used
(n5; PNS).
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for paclitaxel plus SP600125 versus thrombin alone; PNS
for docetaxel plus SP600125 versus thrombin alone; Figure
5D).
Discussion
This study reveals that paclitaxel enhances thrombin-induced
endothelial TF protein expression and surface activity in a
concentration- as well as time-dependent manner via its
stabilizing effect on microtubules and selective activation of
JNK.
Paclitaxel is a lipophilic diterpenoid that binds to the 
subunit of the tubulin heterodimer; this interaction promotes
tubulin polymerization leading to the formation of stable
nonfunctional microtubule bundles and promoting cell cycle
arrest in G2/M phase.26,27 Via this mechanism, paclitaxel
inhibits proliferation as well as migration of vascular smooth
muscle cells and reduces restenosis rates in patients with
Figure 3. Paclitaxel enhances thrombin-induced TF mRNA
expression. A, top, Paclitaxel enhances thrombin-induced TF
mRNA expression in a time-dependent manner (n5; P0.05 vs
thrombin alone). TF mRNA levels are normalized to L28; values
are indicated as percent of TF mRNA expression induced by 2
hours of thrombin stimulation. Bottom, Ct values assessing
the effect of paclitaxel on thrombin-induced TF mRNA expres-
sion at each time point (n5; *P0.05 vs thrombin alone). B,
Effect of paclitaxel on thrombin-induced TF protein expression is
time dependent. A significant increase is observed after incuba-
tion with paclitaxel for 5 and 7 hours (n4; *P0.05 vs thrombin
alone). Values are given as percent of TF expression in
response to 3 hours of thrombin stimulation. Blots are normal-
ized to GAPDH expression.
Figure 4. Paclitaxel enhances thrombin-induced JNK activation.
A, Paclitaxel (105 mol/L) enhances thrombin-induced JNK acti-
vation after 15, 30, and 60 minutes of stimulation (n4; *P0.05
vs thrombin alone). Expression of total JNK is not affected. B,
Paclitaxel (105 mol/L) slightly prolongs maximal p38 phosphor-
ylation. Expression of total p38 is not affected. C, Paclitaxel
(105 mol/L) slightly decreases maximal ERK phosphorylation.
Expression of total ERK is not affected.
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coronary artery disease.3,4,7 Because of its lipophilic proper-
ties, paclitaxel accumulates in the vessel wall, reaching
particularly high concentrations in the intima28,29; local tissue
concentrations are indeed 100-fold higher as compared with
perfusate concentrations during ex vivo endovascular perfu-
sion.28 In a porcine coronary artery stent model, tissue
concentrations of paclitaxel reached 3.2 g/g arterial tissue
after 28 days and drop below detection limit within 3 months
only30; this tissue concentration of paclitaxel corresponds to
3.7106 mol/L at an assumed tissue density of 1 g/cm3.30
Similar tissue concentrations have been measured in a rabbit
iliac artery stent model.31 Thus, the paclitaxel concentrations
used in our study are comparable to local tissue concentra-
tions after stent deployment.
In animal models, partial reendothelialization has been
observed as early as 4 days after DES deployment, whereas
complete reendothelialization occurs within 3 weeks.30,32 In
humans, partial reendothelialization has been documented 2
weeks after stenting and is usually completed within 12
weeks.32,33 Paclitaxel-eluting stents have a biphasic drug-
release profile in vitro, characterized by an initial burst during
the first 48 hours after implantation, followed by a sustained
low-level release for at least 2 weeks.6,34,35 Because of its
lipophilic properties, however, very high paclitaxel concen-
trations have been measured up to 4 weeks after stent
implantation in vivo, and the drug remains detectable for up
to 12 weeks. Therefore, the time course of reendotheli-
alization coincides with the presence of paclitaxel in the
vessel wall after stent deployment. Thus, paclitaxel may
indeed alter the biology of the endothelium within the stented
area.
In-stent thrombosis has been described in patients treated
with paclitaxel-eluting stents, particularly after cessation of
antiplatelet therapy.8,10,12 Our data demonstrate that the effect
of paclitaxel is maintained over prolonged time periods and
that it becomes effective as soon as a stimulus like thrombin
is present; hence, the data are consistent with the clinical
observation that cessation of antiplatelet therapy is a risk
factor for thrombosis of drug-eluting stents. Moreover, in
view of the coronary paclitaxel concentrations after stent
deployment, as well as the time course of reendotheli-
alization, paclitaxel may indeed contribute to the develop-
ment of subacute or late in-stent thrombosis by enhancing
endothelial TF expression. This interpretation is supported by
the results of the SCORE trial, which compared the QuaDDS
stent (coated with the paclitaxel-derivative 7-hexanoyltaxol)
to BMS; the trial had to be terminated prematurely because of
very high rates of subacute and late in-stent thrombosis as
Figure 5. JNK mediates the effect of
paclitaxel and docetaxel on TF expres-
sion. A, Similar to paclitaxel, docetaxel
(106 and 105 mol/L) enhances
thrombin-induced TF expression (n4;
*P0.05 for thrombinpaclitaxel vs
thrombin alone; *P0.005 for
thrombindocetaxel vs thrombin alone;
PNS for thrombinpaclitaxel vs
thrombindocetaxel). Values are given
as percentage of TF expression in
response to 5 hours of thrombin stimula-
tion. Blots are normalized to GAPDH
expression. B, Paclitaxel and docetaxel
enhance JNK phosphorylation as com-
pared with thrombin alone (n4;
*P0.0001 for thrombinpaclitaxel vs
thrombin alone; *P0.05 for
thrombindocetaxel vs thrombin alone;
PNS for thrombindocetaxel vs
thrombinpaclitaxel). Expression of total
JNK is not affected. C, SP600125 (106
mol/L) reduces thrombin-induced TF
expression to 65% of control (n3;
P0.01). D, In the presence of
SP600125 (106 mol/L), the effect of pac-
litaxel and docetaxel on thrombin-
induced TF expression is blunted (n4;
P0.0001 for paclitaxel vs
paclitaxelSP600125; P0.05 for
docetaxel vs docetaxelSP600125;
PNS for paclitaxelSP600125 vs
thrombin alone; PNS for
docetaxelSP600125 vs thrombin
alone).
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well as major adverse cardiac events.13 The increased rates of
in-stent thrombosis have been primarily related to the high
paclitaxel doses released by these stents, although an unfa-
vorable effect of the stent design may have contributed.13
Interestingly, the paclitaxel derivative 7-hexanoyltaxol can be
detected up to 10 mm proximal and distal to the stent
margins, suggesting that paclitaxel may induce TF expression
in the vessel segments proximal and distal to the stent as
well.36
The effect of paclitaxel was attributable to a specific action
on endothelial cell function, as it neither affected cell mor-
phology nor induced any toxicity.37,38 This is consistent with
previous observations demonstrating that paclitaxel (105
mol/L) does not induce any cell death in human pulmonary
artery endothelial cells or aortic smooth muscle cells after 16
and 36 hours of incubation, respectively.38,39 The increase in
TF surface activity was less pronounced than that in protein
expression, which may be related to the presence of inactive
encrypted TF on the cell surface or to the distribution of TF
in several cellular compartments.40
Thrombin induces TF expression at the transcriptional
level via activation of the MAP kinases p38, ERK, and
JNK.21,41 The increase in TF protein expression by paclitaxel
was preceded by an enhanced TF mRNA expression. Con-
sistent with this observation, paclitaxel augmented thrombin-
induced JNK phosphorylation. Interestingly, the activation
pattern of p38 and ERK was not affected, indicating that
paclitaxel selectively activates JNK without affecting other
signal-transduction molecules in endothelial cells. Consistent
with this interpretation, IkB- degradation was not altered by
paclitaxel. Similar observations have been made in different
cancer cell lines, demonstrating that the effect of paclitaxel on
JNK activation is not restricted to the endothelium.42–44 To
assess whether JNK indeed mediates the induction of TF
expression in response to thrombin and, in particular, to
paclitaxel, endothelial cells were pretreated with SP600125, a
selective inhibitor of JNK catalytic activity. SP600125 de-
creased thrombin-induced TF expression by approximately a
third, indicating that JNK is not the only signal-transduction
mediator regulating thrombin-induced TF expression. In con-
trast, the JNK inhibitor fully prevented the effect of pacli-
taxel, strongly suggesting that the effect of paclitaxel on TF
expression is selectively mediated by the JNK pathway.
However, it cannot be ruled out completely that other
signal-transduction pathways may be involved as well.
The microtubule-stabilizing agent docetaxel was used to
elucidate whether the increase in thrombin-induced JNK
activation and TF expression by paclitaxel was related to
perturbation of microtubule function.43 Both microtubule-
stabilizing agents exerted a similar effect on JNK activation
and TF expression, and SP600125 blunted the enhancing
effect of both docetaxel and paclitaxel on thrombin-induced
TF expression. Thus, the action of paclitaxel on JNK activa-
tion and TF expression seems to depend on stabilization of
microtubule bundles rather than on a substance-specific
effect. Consistent with this interpretation, JNK activation in
response to changes in the microtubule cytoskeleton has been
described in different cancer cell lines.43,44
Paclitaxel enhanced thrombin-induced endothelial TF ex-
pression by 2.1-fold. Rapamycin augmented thrombin-
induced TF expression to a similar extent, whereas the
mechanisms of action of the 2 drugs differ completely:
binding of rapamycin to its intracellular receptor FKBP-12
abrogates p70S6 kinase phosphorylation, leading to enhanced
endothelial TF expression; whereas JNK activation remains
unaffected.21 Large-scale clinical trials have demonstrated
that patients receiving paclitaxel-eluting stents have similar
rates of in-stent thrombosis as compared with rapamycin-
eluting stents.11,45 This observation is consistent with the
similar degree of TF induction in endothelial cells, suggesting
that the latter may indeed be importantly involved in throm-
bosis of DES.
In conclusion, this study indicates that paclitaxel increases
endothelial TF expression via JNK activation because of its
microtubule stabilizing effect. The enhanced endothelial TF
expression may favor thrombus formation after paclitaxel-
eluting stent deployment, particularly when antithrombotic
drugs are withdrawn or thrombin levels are elevated as it
occurs in acute coronary syndromes. Therefore, these find-
ings may have interesting implications for drug-eluting stent
design.
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Tissue Factor in Cardiovascular Diseases
Molecular Mechanisms and Clinical Implications
Jan Steffel, MD; Thomas F. Lüscher, MD; Felix C. Tanner, MD
Abstract—Tissue factor (TF), formerly known as thromboplastin, is the key initiator of the coagulation cascade; it binds
factor VIIa resulting in activation of factor IX and factor X, ultimately leading to fibrin formation. TF expression and
activity can be induced in endothelial cells, vascular smooth muscle cells, and monocytes by various stimuli such as
cytokines, growth factors, and biogenic amines. These mediators act through diverse signal transduction mechanisms
including MAP kinases, PI3-kinase, and protein kinase C. Cellular TF is present in three pools as surface, encrypted,
and intracellular protein. TF can also be detected in the bloodstream, referred to as circulating or blood-borne TF.
Elevated levels of TF are observed in patients with cardiovascular risk factors such as hypertension, diabetes,
dyslipidemia, and smoking as well as in those with acute coronary syndromes. TF may indeed be involved in the
pathogenesis of atherosclerosis by promoting thrombus formation; in addition, it can induce migration and proliferation
of vascular smooth muscle cells. As a consequence, therapeutic strategies have been developed to specifically interfere
with the action of TF such as antibodies against TF, site-inactivated factor VIIa, or recombinant TF pathway inhibitor.
Inhibition of TF action appears to be an attractive target for the treatment of cardiovascular diseases. (Circulation. 2006;
113:722-731.)
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Tissue factor (TF) has long been known as a key initiatorof the coagulation cascade. Over the last decade, our
understanding of the molecular regulation of TF expression in
vascular cells has profoundly improved; moreover, TF has
been recognized to be involved in the pathogenesis of
cardiovascular diseases. Therefore, therapeutic strategies are
being developed to specifically interfere with TF and its
effectors.
We will review the molecular regulation of TF expression
emphasizing the role of TF in cardiovascular diseases as well
as the resulting implications for the treatment of atheroscle-
rosis and acute coronary syndromes.
Molecular Mechanisms of Tissue
Factor Expression
Tissue factor, formerly known as thromboplastin, is a 47-kDa
protein expressed in both vascular and nonvascular cells. The
TF gene is located on chromosome 1 and consists of 6 exons.1
One main transcript as well as at least one alternatively
spliced form have been described.2 In the vessel wall, TF is
constitutively expressed in subendothelial cells such as vas-
cular smooth muscle cells leading to rapid initiation of
coagulation when the vessel is damaged.3 In contrast, endo-
thelial cells and monocytes do not express TF under physio-
logical conditions; as a consequence, there is no appreciable
contact of cellular TF with the circulating blood. In response
to various stimuli, however, TF expression and activity can
be induced in these cells as well.
The coagulation cascade is initiated as soon as TF comes
into contact with circulating activated factor VII (VIIa),
resulting in the TF-FVIIa complex (Figure 1). Alternatively,
TF can bind inactive factor VII and form the TF-FVII
complex, which is converted to TF-FVIIa by FVIIa or already
formed TF-FVIIa. The TF-VIIa complex activates factor IX,
which in turn activates factor X; alternatively, factor X is
directly converted to factor Xa by TF-FVIIa. In complex with
factor Va and calcium, Factor Xa catalyzes the conversion of
prothrombin to thrombin, thereby leading to fibrin formation,
platelet activation, and, ultimately, generation of a thrombus.
Several of these activated proteases, including factor IXa,
factor Xa, thrombin, and the TF-VIIa complex itself, can
convert factor VII to VIIa in an auto-feedback loop.
In addition to its well-established role in coagulation, TF
participates in other cellular processes. It is involved in
migration and proliferation of vascular smooth muscle cells.4
Furthermore, the development of embryonic blood vessels is
critically dependent on TF because mice lacking TF die
beyond embryonic day 8.5 secondary to abnormal circulation
from yolk sac to embryo.5 TF has also been observed to
promote tumor neovascularization and metastasis.
Over the last years, our knowledge of the molecular
mechanisms regulating TF expression as well as its biological
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action in vascular cells has greatly advanced and is delineated
in this section.
Endothelial Cells
Endothelial TF is induced by cytokines such as tumor
necrosis factor- (TNF-),6 interleukin-1,7 or CD40 li-
gand,8 by biogenic amines such as serotonin9 or histamine,10
and by mediators such as thrombin, oxidized LDL, or
vascular endothelial growth factor (Figure 2).11–13 Despite
their diversity, most of these mediators share similar signal
transduction pathways regulating TF induction. The MAP
kinases p38, p44/42 (ERK), and c-jun terminal NH2-kinase
(JNK) are involved in TNF-–induced, histamine-induced,
and thrombin-induced TF expression,6,10,12,14 whereas the
effect of vascular endothelial growth factor (VEGF) is only
mediated by p38 and ERK.14 TNF- and VEGF are known to
induce TF expression through activation of protein kinase C
as well.14 These signal transduction molecules stimulate the
TF promoter by activating transcription factors such as AP-1,
nuclear factor (NF)-B, and EGR-1,8,14,15 ultimately resulting
in upregulation of TF mRNA.13,15–17 Regulation of the TF
promoter is reviewed in detail elsewhere.15
Unlike MAP kinases or protein kinase C, the PI3-kinase
pathway negatively regulates endothelial TF expression; as a
consequence, inhibition of PI3-kinase or its downstream
mediators increases TF expression in response to TNF-,
histamine, thrombin, and VEGF.12,16,18,19 The mechanism of
the enhanced endothelial TF expression on PI3-kinase inhi-
bition has not yet been elucidated in detail. Downstream
targets of PI3-kinase such as the mammalian target of
rapamycin are known to be involved in the regulation of
protein translation, which may at least in part account for
their effect on TF expression.16 In one study, VEGF-induced
p38 activation was enhanced when PI3-kinase was blocked
by wortmannin19; hence, cross-talk to MAP kinases may
explain the inhibitory role of the PI3-kinase pathway on
VEGF-induced TF expression. In contrast, such cross-talk is
not observed in response to thrombin,16 indicating that the
molecular events underlying the effect of PI3-kinase on
endothelial TF expression differ with the particular stimulus
involved.
The extent of TF protein induction in vascular cells does
not always correlate well with TF activity.10,11 One possible
explanation is the concomitant secretion of tissue factor
pathway inhibitor (TFPI), the endogenous inhibitor of TF.
Another possible reason is the distribution of TF into several
cellular compartments.11,20 Biologically active TF is indeed
located at the cell surface, whereas intracellular TF consti-
tutes a pool that is only released on cell damage. A combi-
nation of TNF- and VEGF favors cell surface over intracel-
Figure 1. Tissue factor: A key regulator
of coagulation. Tissue factor (TF) is a key
initiator of the coagulation cascade. For-
mation of a complex with factor VIIa
(FVIIa) leads to activation of factor IX
(FIX) and factor X (FX), resulting in
thrombin generation and, ultimately, clot
formation. Tissue factor pathway inhibitor
(TFPI), the endogenous inhibitor of TF
activity, is synthesized and secreted
mainly by endothelial cells. TFPI binds to
FXa and thereby inhibits TF/FVIIa
activity.
Figure 2. Induction of tissue factor expression and activity. Induction of tissue factor (TF) is exemplified in an endothelial cell. Various
mediators induce TF expression through activation of their receptors. Induction of TF primarily occurs at the transcriptional level, result-
ing in an increase in TF mRNA and, eventually, TF protein expression. TF is distributed in three cellular pools as cytoplasmatic TF, sur-
face TF, and encrypted TF. Moreover, TF-containing microparticles are released from the cell. Alternative splicing results in a soluble
secreted form of TF (asTF). IL-1 indicates interleukin-1; LPS, lipopolysaccharide; TNF-, tumor necrosis factor ; VEGF, vascular en-
dothelial growth factor; HB1B, histamine HB1B-receptor; 5-HTB2aB, 5-hydroxytryptamineB2aB receptor; IL1-R, interleukin-1 receptor;
TLR-4, toll-like receptor 4; PAR, protease-activated receptor; KDR, VEGF receptor-2.
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lular distribution as compared with stimulation with either
agonist alone, suggesting a complex regulation of the cellular
distribution of TF.11 Discrepancies between TF protein ex-
pression and activity can further be accounted for by the
induction of a functionally inactive form of TF at the cell
surface, termed latent or encrypted tissue factor. Expression
of encrypted TF enables a cell to rapidly increase TF activity
in response to certain stimuli without the need for de novo
protein synthesis because de-encryption of TF has been
observed secondary to changes in intracellular calcium levels,
alterations in membrane phosphatidylserine expression, or
modifications in the quaternary structure of TF.21 Hence, the
relative contribution of TF protein induction, cellular local-
ization, and structural modification appears to determine the
net procoagulant effect elicited by a given mediator.
Vascular Smooth Muscle Cells
In normal arteries, low levels of TF are found in the medial
layer.3 Similarly, vascular smooth muscle cells in culture
express low basal levels of TF.10,20,22,23 Mediators such as
TNF-, CD40 ligand, histamine, thrombin, endotoxin, and
PDGF-BB as well as aggregated LDL and lysophosphatidic
acid induce TF expression in vascular smooth muscle
cells.10,20,22,24–28 In general, the extent of inducibility in
response to these mediators appears to be lower than that
observed in endothelial cells or monocytes. Relatively few
studies have investigated the molecular mechanisms regulat-
ing TF expression in vascular smooth muscle cells. Similar to
endothelial cells, an involvement of MAP kinases and PI3-
kinase has been observed. In human vascular smooth muscle
cells, p38 and PI3-kinase mediate thrombin-induced TF
expression.26 In rat vascular smooth muscle cells, ERK is
involved in TF expression to lysophosphatidic acid28 and
PDGF-BB,25 whereas p38 and PI3-kinase do not play a role.
Hence, the effect of MAP kinases and the PI3 kinase pathway
appears to depend on the particular stimulus and/or the
species involved.
Similar to endothelial cells, induction of vascular smooth
muscle cell TF expression is only to some extent reflected in
an increased TF activity.20 Consistent with this observation,
vascular smooth muscle cell TF is found in three cellular
pools, namely as surface TF, encrypted TF, and intracellular
TF.20,29
Monocytes and Macrophages
Monocytes, like endothelial cells, show very little to no basal
expression of TF. Its expression can, however, be induced by
inflammatory stimuli such as C-reactive protein30 or CD40
ligand.31 PDGF-BB, angiotensin II, and oxidized LDL32,33
have also been observed to induce TF in monocytes; yet one
of the most extensively studied stimuli in this cell type is
endotoxin.15,34 p38, ERK, and JNK are all involved in
lipopolysaccharide-induced monocyte TF expression34 lead-
ing to nuclear translocation of the transcription factors
EGR-1, c-Fos/c-Jun, and c-Rel/p65. Ultimately, binding of
these transcription factors to the EGR-1, AP-1, and NF-B
sites of the TF promoter mediates the endotoxin-induced
increase in TF mRNA transcription.15 Similar to endothelial
cells, the PI3 kinase pathway exerts an inhibitory influence on
TF induction in this cell type, and at least part of this action
occurs through cross-talk with MAP kinases.34
Type 1 (TH1) but not type 2 helper T cells (TH2) secrete
mainly proinflammatory mediators such as TNF- and inter-
feron (IFN)-, which are involved in macrophage activa-
tion.35 Cytokines derived from TH1 cells as well as cell-to-
cell contact with TH1 cells induces TF expression in
monocytes.36 Transformation of monocyte-derived macro-
phages into foam cells results in increased TF expression as
well.37 In contrast, TH2-derived mediators such as IL-4,
IL-10, and IL-13 prevent TH1-induced TF expression.36 Thus,
consistent with their role in macrophage activation and
atherogenesis, proinflammatory stimuli released from TH1
cells upregulate TF expression, whereas cytokines derived
from TH2 cells inhibit this effect.
Blood-Borne Tissue Factor
Tissue factor is not only present in vascular cells or leuko-
cytes but can also be detected in the bloodstream, referred to
as circulating or blood-borne TF.38 This form of TF is mainly
associated with microparticles39 originating from endothelial
cells, vascular smooth muscle cells, leukocytes, or plate-
lets.22,40 In addition, TF containing microparticles are re-
leased from atherosclerotic plaques.39
Monocytes and platelets are known to exchange
microparticle-bound TF.41 Because megakaryocytes, the bone
marrow sedentary precursors of platelets, do not express TF,
it is likely that this exchange represents a mechanism through
which platelets are loaded with TF. In addition to carrying
microparticle-derived TF, activated platelets induce tissue
factor expression in human endothelial and smooth muscle
cells, presumably by releasing soluble mediators such as
serotonin and PDGF.42 Aggregating platelets thus induce a
positive feedback loop that enhances local TF concentrations
through two mechanisms and may be important for thrombus
formation and/or propagation.
Recently, an alternatively spliced form of TF has been
discovered, which is soluble, circulates in the blood, and
exhibits procoagulant activity.2 Cytokines stimulate its ex-
pression in and release from endothelial cells.43 Alternatively
spliced TF is not bound to microparticles and appears to
represent a distinct form of circulating TF; as such, it may
have an important role in thrombus propagation.43 Indeed,
soluble TF may be particularly important in this context, as
vessel wall–associated TF, being separated from the blood-
stream by the freshly formed thrombus, may be prevented
from contributing to thrombus growth.44
These studies on blood-borne TF imply that activation of
coagulation, contrary to traditional belief, may be initiated
and propagated without contact of the blood to the extravas-
cular space. The importance of blood-borne versus vessel
wall-associated TF is currently a subject of debate.44–46 One
study described that TF from leukocyte-derived micropar-
ticles importantly contributes to thrombus propagation in an
animal model of thrombosis,44 whereas another one identified
vessel wall–derived TF as the primary mediator driving
thrombus formation after vascular injury.45 It is also contro-
versial whether physiological concentrations of circulating
TF can exhibit clot-forming activity in vivo.47 Thus, the
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relative contribution of soluble TF, microparticle-bound TF,
and vessel wall–associated TF to initiation and propagation of
thrombosis requires further study.
Tissue Factor in Cardiovascular Diseases
Tissue factor has been implicated in the pathogenesis of
several cardiovascular disorders. The following section sum-
marizes its involvement in cardiovascular risk factors such as
hypertension, diabetes, dyslipidemia, and smoking; its role in
atherosclerosis and acute coronary syndromes is discussed as
well.
Cardiovascular Risk Factors
Tissue factor plasma antigen is elevated in hypertensive
subjects as compared with normotensive control subjects and
can be lowered by different classes of antihypertensive
drugs.48 Of particular interest is the observation that angio-
tensin II induces TF expression in monocytes, endothelial
cells, and vascular smooth muscle cells24,32 through the
angiotensin II type I receptor (AT-I).32 Consistently, both
ACE inhibitors49 and AT-I receptor blockers50 reduce TF
plasma activity in hypertensive patients. ACE inhibitors also
reduce endotoxin-induced TF expression in monocytes,51
suggesting a pleiotropic effect of this class of drugs.
High glucose concentrations increase thrombin-induced TF
expression in human endothelial cells.52 Similarly, glucose
intake upregulates TF expression in monocytes of healthy
humans. Hyperglycemia leads to the formation of advanced
glycation end-products (AGE), which induce TF expression
in endothelial cells through the receptor for advanced glyca-
tion end-products (RAGE) and activation of NF-B.53,54
Consistent with this observation, diabetic ApoE-/- mice dis-
play increased vascular expression of RAGE and TF55;
moreover, blockade of RAGE suppresses TF levels in the
aorta of these mice, which may have interesting implications
for the pathogenesis and treatment of diabetic vasculopathy.55
In diabetic patients, increased TF plasma levels are measured
even without overt coronary artery disease,56 and TF levels
are reduced by improving glycemic control.57 In obese
nondiabetic subjects, insulin reduces both monocyte TF
expression and TF plasma levels, which occurs due to a
reduced activation of the proinflammatory transcription fac-
tor EGR-1, suggesting that insulin exerts its beneficial effects
not only through improving hyperglycemia.58
Oxidized LDL increases TF expression in endothelial
cells,13 monocytes, and macrophages,33 whereas reconstituted
HDL inhibits thrombin-induced endothelial TF expression.18
Consistent with these observations, patients with elevated
LDL levels display raised TF plasma activity.57 HMG-CoA
reductase inhibitors (statins), the most widely used drugs for
the treatment of hypercholesterolemia, reduce TF expression
in monocytes, endothelial cells, and vascular smooth muscle
cells.12,59 In apoE knockout mice, simvastatin inhibits TF
expression in advanced atherosclerotic lesions independent of
plasma lipid levels.60 Hence, the reduction of TF expression
by statins is at least in part related to the pleiotropic
antiinflammatory effects of this class of drugs. Consistent
with this interpretation, endotoxin-induced TF expression is
blunted after administration of simvastatin to healthy hu-
mans.61 Fibric acid derivatives are another class of drugs used
to treat patients with dyslipidemia. Through activation of the
peroxisome proliferator-activated receptor–alpha (PPAR-),
these drugs reduce TF expression in human monocytes and
macrophages, which may in part be responsible for their
beneficial effect in patients with cardiovascular diseases.62
Exposure of apoE knockout mice to cigarette smoke results
in an increased TF expression in atherosclerotic plaques as
compared with mice breathing filtered room air.63 Cigarette
smoking is associated with increased TF plasma levels in
humans as well; indeed, a strong correlation is observed
between the number of cigarettes smoked and TF plasma
levels.57
These data indicate that TF may be involved in the
proatherosclerotic effect of cardiovascular risk factors. It
cannot be ruled out, however, that some of the observed
elevations in TF plasma levels occur secondary to TF release
from already established atherosclerotic plaques.
Atherosclerosis
Monocytes infiltrate the intimal layer and then transform into
macrophages and foam cells, which represents a hallmark of
the inflammatory nature of atherosclerosis.35 In this inflam-
matory environment, cytokines such as TNF- and interleu-
kins are released and induce expression of TF. During the
early stages of atherogenesis, enhanced TF expression is
observed in monocytes3; at later stages, TF expression is also
detected in foam cells, endothelial cells, and smooth muscle
cells.3,64 TF is present in the necrotic core of plaques as well,
predominantly associated with microparticles derived from
perishing foam cells, macrophages, or lymphocytes.39,64 Such
microparticles indeed contain the major part of the TF
activity in atherosclerotic plaques.39 Consistent with these
observations, TF expression is closely associated with apo-
ptosis of macrophages in lipid-rich plaques,65 which adds to
the evidence that not only inflammation but also apoptosis
can determine plaque thrombogenicity.
Increasing size of atherosclerotic plaques can lead to
vascular stenosis, which is associated with enhanced shear
forces promoting endothelial TF expression. In most in-
stances, however, it is not the degree of luminal narrowing,
but rather the composition of the plaque which determines the
clinical course of events. Lipid-rich plaques with a thin cap,
a large lipid core, extensive macrophage infiltration, and
abundant TF expression are more prone to rupture than
collagen-rich, fibrous plaques. Rupture of an atherosclerotic
plaque exposes its highly procoagulant content to the circu-
lating blood; thereby, TF-laden macrophages as well as
TF-containing microparticles originating from the necrotic
core initiate thrombus formation and related complications
such as acute myocardial infarction (Figure 3).
Besides activation of the coagulation cascade, TF is in-
volved in other pathogenetic events occurring during the
formation of atherosclerotic lesions. TF is the receptor for
factor VIIa and as such mediates responses such as migra-
tion66 and proliferation of vascular smooth muscle cells.67
These processes are importantly involved in vascular remod-
eling, because vascular smooth muscle cells migrate into and
proliferate within the neointima of injured vessels. The effect
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of the TF/FVIIa complex on migration and proliferation of
vascular smooth muscle cells is critically dependent on the
cytoplasmic domain of TF, as vascular remodeling in re-
sponse to injury is reduced in mice lacking this domain.68
Recruitment of microvessels into atherosclerotic plaques can
lead to plaque progression by contributing to plaque destabi-
lization and rupture.35 As TF is involved in angiogenesis,5 it
may also play a role in plaque neovascularization and thereby
promote plaque destabilization. Thus, evidence is emerging
that TF may not only be involved in atherogenesis by eliciting
thrombosis but also by direct actions on vascular remodeling
and plaque progression or instability.
Acute Coronary Syndrome and Percutaneous
Coronary Intervention
Increased levels of TF antigen and activity are detected in
atherectomy specimens from patients with unstable angina or
myocardial infarction as compared with those with stable
angina.69 In acute coronary syndromes, plasma concentra-
tions of inflammatory cytokines such as TNF- and interleu-
kins are indeed increased at the site of coronary artery
occlusion to such an extent that TF is induced in vascular
cells.70 Hence, vascular cells as well as circulating leukocytes
and aggregating platelets may be a source of the elevated
levels of circulating TF measured in patients with acute
coronary syndrome.71 As plaque rupture leads to exposure of
highly procoagulant plaque content to the circulation, it may
also contribute to the elevated TF plasma levels.39 Consistent
with this interpretation, patients with unstable angina show
higher TF plasma levels than those with stable angina,72 and
elevated TF plasma levels may even predict future cardiovas-
cular events in patients with unstable angina.72 Because a
substantial number of patients with acute myocardial infarc-
tion have coronary artery thrombi on top of a superficial
erosion, increased TF plasma levels in these patients may also
originate from endothelial erosions of atherosclerotic le-
sions.73 Interestingly, several polymorphisms of the TF gene
are known, and recent data suggest that certain genetic
variations in the TF gene as well as the TF promoter may be
associated with a worse outcome in patients with acute
coronary syndrome, possibly through increased monocyte TF
expression.74,75
Selective cyclooxygenase-2 inhibitors (coxibs), rofecoxib
in particular, have come under scrutiny as they are suspected
of causing thrombotic complications in patients with cardio-
vascular diseases. This effect is believed to depend on
inhibition of prostacyclin formation. Large-scale epidemio-
logical studies have indeed suggested that rofecoxib intake is
associated with an increased risk of myocardial infarction.76
This association, however, is not observed with celecoxib,
which may be related to inhibition of TF expression by this
coxib in endothelial cells.6 Given the importance of TF in the
pathogenesis of acute coronary syndromes, this effect may
account for the different occurrence of thrombotic complica-
tions between coxibs observed in epidemiological studies.76
As neither rofecoxib nor the experimental coxib NS-398
inhibit endothelial TF expression, the effect of celecoxib
appears to occur independent of cyclooxygenase inhibition;
instead, it is mediated by decreasing TNF-–induced JNK
phosphorylation.6
Because platelets represent a major source of TF, it is
conceivable that antiplatelet drugs, which are used for treat-
ing acute coronary syndromes, reduce TF expression as well
as TF plasma levels. Indeed, the ADP receptor antagonist
clopidogrel reduces TF expression in the ischemic coronary
artery in an animal model of acute myocardial infarction.77
Moreover, as interaction with platelets induces TF expression
in monocytes, the GPIIb/IIIa antagonist abciximab suppresses
monocyte TF expression and activity by reducing platelet-
monocyte cross-talk; likewise, abciximab reduces monocyte
TF expression in patients undergoing carotid angioplasty with
stenting.78 Aspirin, however, inhibits endotoxin-induced tran-
Figure 3. Tissue factor in the atheroscle-
rotic plaque. In the inflammatory environ-
ment of atherosclerotic plaques, tissue
factor (TF) is present at high levels in en-
dothelial cells, vascular smooth muscle
cells, macrophages/foam cells, and in
the necrotic core. TF induction is exem-
plified by selected mediators in endothe-
lial cells (EC, left panel), macrophages
(M, middle panel), and vascular smooth
muscle cells (VSMC, right panel). On
plaque rupture, highly procoagulant
material including TF-containing micro-
particles is released into the blood, lead-
ing to rapid initiation of coagulation,
platelet aggregation, and, ultimately,
thrombus formation with vessel
occlusion.
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scriptional activation of TF expression in monocytes and may
thus reduce TF plasma activity by direct actions on the
regulation of TF expression as well.79 In contrast to these
agents, long-term treatment with the oral anticoagulant war-
farin increases soluble TF levels, probably as the result of
decreased TF consumption.80
Percutaneous coronary intervention is the preferred treat-
ment for patients presenting with acute myocardial infarction.
It is unclear whether or not TF plasma levels are increased
after percutaneous coronary intervention, as some groups
found an increase whereas others did not.81 It is conceivable
that plaque dissection caused by balloon dilation may lead to
exposure of plaque content to the bloodstream and thereby
increase TF plasma levels. In the reperfusion phase, oxygen-
derived free radicals were observed to mediate TF induction,
whereas continuous inflammatory alterations of the athero-
sclerotic coronary arteries may increase TF levels at later
stages.82 If present, increased TF levels have a negative
prognostic value with regard to the development of restenosis
after percutaneous coronary angioplasty with or without
stenting.81 This effect may well be related to the promigratory
and proproliferative action of TF on vascular smooth muscle
cells, which are known to contribute to the development of
restenosis.4,66,67
Drug-eluting stents are covered with pharmacological
agents, which, once released into the coronary artery after
stent deployment, inhibit vascular smooth muscle cell prolif-
eration and thereby restenosis. In contrast to reduced reste-
nosis rates, however, the frequency of stent thromboses has
not decreased with drug-eluting stents as compared with bare
metal stents.83 Rapamycin, which is used for stent coating,
increases endothelial TF expression, suggesting a potential
role for this drug in the development of subacute stent
thrombosis.16 As this effect on TF expression is not observed
with FK-506, another agent used on drug-eluting stents,
application of FK-506-eluting stents may provide a more
favorable environment for the development of in-stent throm-
bosis.16 However, additional studies are needed to assess the
implications of these findings in vivo. Platelet activation is a
crucial event in the pathogenesis of thrombus formation. The
use of platelet receptor antagonists such as clopidogrel has
indeed reduced the incidence of stent thrombosis, whereas
withdrawal of antiplatelet therapy favors thrombus forma-
tion.83 Clopidogrel inhibits the release of TF from aggregat-
ing platelets, which is of particular importance, as platelet
aggregation and secretion are increased in human platelets
treated with rapamycin.84 Therefore, it will be of great
interest to study the dynamic interaction between rapamycin
and platelet activation as well as the spatio-temporal pattern
of TF expression in the arterial wall after deployment of
drug-eluting stents.
Therapeutic Implications
Various agents have been developed to specifically interfere
with the action of TF and the TF/FVIIa complex (Figure 4).
In contrast to classic antithrombotic drugs, these agents target
the first steps of coagulation while leaving the downstream
effectors intact. In addition, these drugs can interfere with
promigratory or proproliferative effects of TF. In this section,
we will focus on recently developed drugs specifically
targeting TF, whereas nonspecific inhibitors will not be
discussed.
Inhibition of TF Synthesis
A hairpin ribozyme, which destroys TF mRNA, abrogated
induction of TF protein expression and activity in vascular
smooth muscle cells.85 Similarly, antisense oligonucleotides,
hybridizing to their complementary target mRNA and thereby
preventing translation, inhibited TF induction in monocytes.86
An alternative approach takes advantage of curcumin, a
naturally occurring pigment suppressing the activation of the
transcription factors Egr-1, AP-1, and NF-B, and resulting
in inhibition of TNF-–induced endothelial TF induction.87
Figure 4. Therapeutic approaches. Sev-
eral therapeutic strategies have been
developed to specifically interfere with
the action of tissue factor (TF). Molecular
approaches such as ribozymes or anti-
sense oligonucleotides specifically inhibit
TF production. Monoclonal or polyclonal
anti-TF antibodies directly target and in-
activate the TF protein. Site-inactivated
factor VIIa (FVIIai) binds to TF but lacks
catalytic activity for conversion of factor
X (FX) or factor IX (FIX). Recombinant
tissue factor pathway inhibitor (rTFPI)
interferes with the activity of the TF/FVIIa
complex by binding to the active site of
factor Xa (FXa), leading to formation of a
quaternary inhibitory complex with
TF/FVIIa. Similarly, recombinant nema-
tode anticoagulant protein c2 (rNAPc2)
interferes with the TF/FVIIa complex by
binding to FXa or FX before formation of
a quarternary inhibitory complex with
TF/FVIIa.
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Although novel and intriguing, the clinical applicability of
these approaches has not yet been examined.
Direct Inhibition of TF Action
Different antibody preparations directed against the TF anti-
gen (TF Ab) have been tested in vivo. In a rabbit carotid
artery thrombosis model, a monoclonal anti–TF Ab inhibited
thrombus formation and shortened tissue plasminogen acti-
vator lysis time.88 Similarly, administration of a monoclonal
anti–TF Ab reduced infarct size in a rabbit coronary artery
ligation model as the result of reduced chemokine expression
and leukocyte infiltration.89 In humans, a polyclonal anti–TF
Ab reduced thrombogenicity of disrupted atherosclerotic
plaques by impairing platelet and fibrin deposition.90 In a
recent dose-escalating trial, a chimeric monoclonal anti–TF
Ab potently inhibited thrombin formation in patients with
stable coronary artery disease.91
An alternative approach consists of a mutant form of TF,
which binds to factor VIIa but exhibits reduced catalytic
activity.92 In a rabbit model of arterial thrombosis, this
protein displayed potent antithrombotic properties while
causing less bleeding than heparin.92 Another mutated form
of TF exhibited antithrombotic properties in a guinea pig
model of recurrent arterial thrombosis.93
Active-Site Inactivated Factor VIIa
Active-site inactivated factor VIIa (FVIIai) binds to TF but
lacks catalytic activity; as such, it competes for TF with the
physiologically occurring form of factor VIIa. Several animal
studies examined the effect of FVIIai in vivo, demonstrating
decreased recurrent arterial thrombosis, reduced infarct size,
and improved no-reflow phenomenon; after administration of
a single dose, the effect of FVIIai was long-lasting without
affecting systemic hemostatic parameters.94 Application of a
structurally different but functionally similar site-inactivated
factor VIIa compound reduced restenosis in a femoral artery
injury model,95 which may in part be due to the fact that TF
as well as several downstream coagulation factors stimulate
vascular smooth muscle cell migration and proliferation.66,67
Recombinant Tissue Factor Pathway Inhibitor
Tissue factor activity is counterbalanced by its endogenous
inhibitor, TFPI. TFPI interferes with activity of the TF/FVIIa
complex by binding to the active site of FXa leading to
formation of a quaternary complex with TF/FVIIa. Under
physiological conditions, TFPI is mainly synthesized and
released by endothelial cells. In animal models, recombinant
TFPI (rTFPI) reduced fibrin deposition and neointimal thick-
ening after balloon injury.96 In human atherosclerotic arteries,
rTFPI diminished plaque thrombogenicity by inhibiting plate-
let and fibrin deposition.90
Adenoviral gene transfer represents an alternative ap-
proach for application of a recombinant protein.97 Adenoviral
overexpression of TFPI in injured arteries inhibited recurrent
thrombosis induced by shear stress without affecting systemic
coagulation parameters.98 Similarly, overexpression of TFPI
reduced thrombogenicity as well as vascular remodeling of
balloon-injured atherosclerotic arteries.99
Based on these observations, clinical studies have investi-
gated the safety and efficacy of rTFPI. Initial trials revealed
promising results in various settings; a double-blinded, ran-
domized, phase III trial in patients with severe sepsis and
mild coagulopathy, however, failed to show a clinical benefit
of rTFPI, whereas the frequency of severe adverse events
with bleeding was increased.100 Further studies are needed to
definitively assess the safety and efficacy of rTFPI as a
therapeutic principle.
Nematode Anticoagulant Protein c2
Nematode anticoagulant protein c2 (NAPc2) is isolated from
the saliva of the hookworm Ancylostoma caninum; it inter-
feres with TF activity by binding to factor Xa or factor X
before formation of a quarternary inhibitory complex with
TF/FVIIa. Several studies in primates as well as first studies
in humans revealed very promising results; in a phase II
clinical trial, rNAPc2 indeed appeared safe and effective in
preventing thrombin generation during coronary angioplasty
in combination with aspirin, clopidogrel, and heparin.101
Summary and Conclusions
Over the last years, major advances have been made in
elucidating the molecular regulation of TF expression. Vari-
ous cytokines, growth factors, and biogenic amines have been
recognized to induce TF expression in endothelial cells,
vascular smooth muscle cells, and monocytes. Signal trans-
duction mechanisms specific for both the cell type and the
stimulus involved regulate TF induction and cellular distri-
bution. In addition to cellular TF, an important role of
blood-borne TF is emerging; at present, however, the relative
contribution of vessel wall–associated versus blood-borne TF
to thrombus formation and/or propagation is debated.
Patients with cardiovascular risk factors such as hyperten-
sion, diabetes, dyslipidemia, and smoking have elevated
plasma levels of TF, which may be involved in the proath-
erosclerotic effect of such risk factors. Moreover, TF expres-
sion is upregulated in the inflammatory environment of
atherosclerotic plaques, and large amounts of TF are released
during plaque rupture, leading to thrombus formation and
elevated TF plasma levels in patients with unstable angina
and acute coronary syndromes. As TF simulates vascular
smooth muscle cell migration and proliferation, it may
promote atherogenesis and restenosis not only by initiating
thrombosis but also by direct actions on vascular remodeling
and plaque progression.
Several promising therapeutic strategies have been devel-
oped for targeting the action of TF including antibodies
against TF, site-inactivated factor VIIa, recombinant TFPI,
and recombinant NAPc2. Despite recent setbacks with appli-
cation of rTFPI, interfering with the TF pathway appears to
be an attractive target for the treatment of cardiovascular
diseases.
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Drug-Eluting Stent and Coronary Thrombosis
Biological Mechanisms and Clinical Implications
Thomas F. Lüscher, MD; Jan Steffel, MD; Franz R. Eberli, MD; Michael Joner, MD;
Gaku Nakazawa, MD; Felix C. Tanner, MD; Renu Virmani, MD
Abstract—Although rare, stent thrombosis remains a severe complication after stent implantation owing to its high
morbidity and mortality. Since the introduction of drug-eluting stents (DES), most interventional centers have noted
stent thrombosis up to 3 years after implantation, a complication rarely seen with bare-metal stents. Some data from
large registries and meta-analyses of randomized trials indicate a higher risk for DES thrombosis, whereas others suggest
an absence of such a risk. Several factors are associated with an increased risk of stent thrombosis, including the
procedure itself (stent malapposition and/or underexpansion, number of implanted stents, stent length, persistent slow
coronary blood flow, and dissections), patient and lesion characteristics, stent design, and premature cessation of
antiplatelet drugs. Drugs released from DES exert distinct biological effects, such as activation of signal transduction
pathways and inhibition of cell proliferation. As a result, although primarily aimed at preventing vascular smooth muscle
cell proliferation and migration (ie, key factors in the development of restenosis), they also impair reendothelialization,
which leads to delayed arterial healing, and induce tissue factor expression, which results in a prothrombogenic
environment. In the same way, polymers used to load these drugs have been associated with DES thrombosis. Finally,
DES impair endothelial function of the coronary artery distal to the stent, which potentially promotes the risk of
ischemia and coronary occlusion. Although several reports raise the possibility of a substantially higher risk of stent
thrombosis in DES, evidence remains inconclusive; as a consequence, both large-scale and long-term clinical trials, as
well as further mechanistic studies, are needed. The present review focuses on the pathophysiological mechanisms and
pathological findings of stent thrombosis in DES. (Circulation. 2007;115:1051-1058.)
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With the introduction of balloon-expandable stents, cor-onary remodeling and, in turn, restenosis were reduced
compared with angioplasty alone.1,2 With the risk of resteno-
sis still in the range of 15% to 20%, however, drug-eluting
stents (DES) designed to release pharmacological agents after
deployment were developed to inhibit the response to injury
mainly responsible for restenosis after bare-metal stent
(BMS) implantation (ie, vascular smooth muscle cell migra-
tion and proliferation and proteoglycan deposition). As a
result, restenosis and target-vessel revascularization could be
reduced to rates below 10% after DES implantation.3,4
In the first series of patients receiving BMS, stent throm-
bosis was already recognized as a severe complication after
implantation owing to its high mortality. With the introduc-
tion of P2Y-receptor antagonists (ie, ticlopidine, clopidogrel)
for platelet inhibition in combination with acetylsalicylic
acid, the incidence of stent thrombosis decreased substan-
tially in stable patients to levels as low as 1%.5 Most of the
events occurred within the first 10 days after implantation;
indeed, stent thrombosis after the first month was extremely
rare with BMS.6,7
Despite reduced restenosis rates, the frequency of in-stent
thrombosis has not decreased with DES compared with
BMS.8–12 Indeed, several hundred cases of stent thrombosis
have been reported for rapamycin-coated stents.13 A number
of reports imply that thrombosis rates of DES may even be
higher in the “real world” than in clinical trials.14,15 Notably,
many operators have experienced very late stent thrombosis
(3 years after implantation and beyond) in a number of
patients, which was not seen with BMS. This review will
briefly discuss presently available clinical data and focus on
pathophysiological mechanisms of in-stent thrombosis in
DES.
Clinical Evidence
Numerous reports describe the occurrence of acute (24
hours), subacute (30 days), late (30 days), and very late
(12 months) stent thrombosis after DES implantation.8,13,16
However, the true incidence of stent thrombosis may be
underestimated in clinical trials and could occur at substan-
tially higher rates in the “real-world” setting, where more
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complex lesions are treated.14,15 Given the small size of both
clinical trials and registries and the low absolute number of
stent thromboses, meta-analyses were performed to clarify
this issue. Several meta-analyses initially did not reveal an
increased risk of stent thrombosis with DES compared with
BMS at 9 to 12 months.10,11,12 Subsequently, 3 additional
meta-analyses attracted special attention: In a large analysis
of 8000 patients from 2 academic referral hospitals, a
substantial cumulative incidence of angiographically docu-
mented DES thrombosis was noted (2.9%), yielding a rate of
1.3 per 100 patient-years.17 In that analysis, however, no
patients with BMS were included, and hence, direct compar-
ison of the 2 types of stents was not possible; given the
change in percutaneous coronary intervention practice with
DES, these data are difficult to interpret. In another study
directly comparing DES and BMS, an increase in late
thrombosis was noted in DES.18 Furthermore, a meta-analysis
that included total mortality and Q-wave myocardial infarc-
tion as end points representing the “inclusive clinical surro-
gate of stent thrombosis” found an increased cumulative
incidence of death or myocardial infarction at the latest
available follow-up.9 Because coronary patients experience
new occlusions at sites distant from the implanted stent
and/or fatal arrhythmias, however, such an analysis may
overestimate the true stent thrombosis rate. Moreover, inter-
pretation of meta-analyses is restricted because of their
inherent limitations, which include selective use of end
points, incomplete data sets, and the retrospective nature of
their analysis.
Pathophysiology of In-Stent Thrombosis
Several factors that contribute to stent thrombosis have been
recognized, which are discussed below.
Procedure-Related Factors
Among the procedure-related factors, smaller final lumen
dimensions (stent malapposition and/or underexpansion),
stent length, persistent slow coronary blood flow, placement
of multiple stents, positive remodeling, dissections, geo-
graphic miss, and late stent malapposition due to thrombus
resolution appear to be most important for the development of
in-stent thrombosis.19–25 Also, in DES, stent length, stent
underexpansion, and residual stenosis have been observed to
correlate with an increased risk for stent thrombosis.26,27
These factors are of great interest because they can be
avoided during the intervention, but they are unlikely to differ
between BMS and DES.
Patient- and Lesion-Related Factors
Several patient-related factors have been associated with the
development of in-stent thrombosis, including low ejection
fraction,21 diabetes mellitus,28 advanced age,22 and stenting in
the setting of an acute coronary syndrome.26 Similarly, in
DES, primary stenting in acute myocardial infarction, diabe-
tes mellitus, renal failure, and low ejection fraction appear to
be associated with an increased risk for stent thrombo-
sis.14,26,29,30 In particular, the increased risk in patients with
acute coronary syndrome could be due to delayed healing,
lack of endothelialization, and presence of a pronounced
inflammatory and thrombogenic environment of the exposed
necrotic core to flowing blood, accompanied by enhanced
platelet reactivity; furthermore, rapamycin and paclitaxel
potentiate thrombin-induced expression of tissue factor (see
below).
Furthermore, certain lesion characteristics are reported to
be associated with an increased risk of stent thrombosis. In
DES, this pertains in particular to stenting of bifurcation
lesions or in-stent restenosis lesions.14,29,30 In addition, inter-
ventional practice has changed, with advocates of “normal to
normal” coronary artery stenting and revascularization of
more complex lesions that carry a higher risk of stent
thrombosis. This latter aspect makes comparisons of regis-
tries with historical controls difficult.
Antiplatelet Therapy
Stents are foreign bodies in the vessel wall and thus induce
platelet adhesion and activation of the coagulation cascade.
Furthermore, high-pressure implantation with noncompliant
balloons induces significant vascular injury, with exposure of
thrombogenic molecules of the subintima and media (includ-
ing plaque material) to the blood stream. As a consequence,
only potent platelet inhibition made the procedure feasible,
and antiplatelet hyporesponsiveness has been associated with
an increased risk for stent thrombosis.31 In line with this
observation, discontinuation of antiplatelet therapy has been
observed to be particularly associated with DES thrombo-
sis.8,16,32 The appropriate duration of the long-term antiplate-
let regimen for prevention of DES thrombosis remains to be
assessed in randomized prospective trials; at present, a course
of 12 months of dual-antiplatelet therapy may be considered
especially in high-risk, real-world patients.
Thrombogenicity of the Stent
A predisposition for the development of stent thrombosis has
been observed with certain stent materials; for example,
platelet activation was greater during the 30 days after
implantation of an open-cell versus a closed-cell stent.33 Stent
strut thickness and polymer type and thickness also play an
important role. It has been reported previously that the
nonerodable polymers of the Cypher and Taxus DES provoke
chronic eosinophilic infiltration of the arterial wall, sugges-
tive of hypersensitivity reactions in a small number of
cases.7,34 However, the causal relationship between polymer-
induced inflammation and the incidence of late stent throm-
bosis has only been proven in a minority of patients possess-
ing a proinflammatory phenotype. Detailed analysis of the
morphological changes shows a localized immune response,
with predominance of CD45-positive lymphocytes and eosin-
ophils. In fact, our experience shows that all cases of
hypersensitivity occur 4 months after DES implantation.7
The preclinical experience in a pig model also shows a
progressive increase in the presence of granulomatous reac-
tions, including eosinophilic infiltrate, starting at 28 days
after Cypher stent implantation: 1 month, 14%; 3 months,
43%; 6 months, 60% (R.V., unpublished data). One possible
explanation of these findings is that the hypersensitivity
reaction peaks after the complete release of the drug and is
likely related to the polymer. In addition, positive remodeling
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has been observed in vessels showing a hypersensitivity
reaction.
Furthermore, drugs loaded on DES may exert a prothrom-
bogenic effect. Rapamycin (sirolimus), a macrocyclic lac-
tone, is used on DES, because it is known to inhibit
proliferation and migration of vascular smooth muscle cells,
important factors in the development of neointima formation
and restenosis, through interference with cell cycle regula-
tors.35,36 On a subcellular level, rapamycin binds to the
FK-binding protein 12 and subsequently inhibits the mam-
malian target of rapamycin. The mammalian target of rapa-
mycin is a downstream target of the phosphatidylinositol-3
kinase pathway, which in turn is involved in an inhibitory
fashion in the regulation of tissue factor in endothelial cells
and monocytes.37–39 As a result, rapamycin inhibition of the
mammalian target of rapamycin increases both thrombin- and
tumor necrosis factor-–induced endothelial tissue factor
expression and activity at concentrations of rapamycin that
are encountered in vivo (Figure 1).38,40
Paclitaxel is a lipophilic diterpenoid that binds to the
-subunit of the tubulin heterodimer, promoting tubulin
polymerization, cell cycle arrest, and, eventually, inhibition
of vascular smooth muscle cell migration and prolifera-
tion.41,42 In addition, paclitaxel is known to activate c-Jun
NH2-terminal kinase,43,44 an important mediator of endothe-
lial and monocytic tissue factor induction.37,39,45 Conse-
quently, paclitaxel also enhances tissue factor expression and
activity in endothelial cells44; again, concentrations used in
this in vitro study are comparable with local tissue concen-
trations of paclitaxel after stent deployment.46
In sirolimus-eluting stents, 80% of the rapamycin has
eluted by 30 days, whereas paclitaxel-eluting stents have a
biphasic drug release profile in vitro with an initial burst
during the first 48 hours after implantation followed by a
sustained low-level release for at least 2 weeks.47 However,
both rapamycin and paclitaxel easily penetrate into cells of
the vessel wall owing to their lipophilic properties, which
leads to chronic retention of the drug in the arterial tis-
sue.19,46,48 Thus, both rapamycin- and paclitaxel-induced
tissue factor expression may contribute to a prothrombotic
environment after deployment of DES, particularly in the
acute and subacute setting and possibly in late stent throm-
bosis (Figure 1). The relationship between these findings and
stent thrombosis in clinical practice requires further study,
particularly to examine the degree and the spatiotemporal
pattern of tissue factor expression in the arterial wall after
deployment of DES.
Impaired Reendothelialization
Reendothelialization occurs after vascular injury and simi-
larly after stent placement. Traditionally, it was believed that
endothelial cells proliferate and migrate from intact neigh-
boring coronary segments, eventually leading to the reendo-
thelialization of the injured segment. In vitro, rapamycin and
paclitaxel not only inhibit proliferation and migration of
vascular smooth muscle cells but equally suppress endothelial
cells,7,35,36,38,49–51 thereby potentially impeding reendotheli-
alization (Figure 2). We observed poor endothelial cell
junction formation and microthrombi of focal platelet aggre-
gation at 16 months after rapamycin stent implantation in a
patient dying of a non-DES–related cause.52 It has been
proposed that bone marrow–derived endothelial progenitor
cells may also be involved in reendothelialization.53,54 Inter-
estingly, rapamycin inhibits proliferation, migration, and
differentiation of human endothelial progenitor cells in
vitro.55,56 Hence, drugs loaded on DES may affect the number
as well as the homing and proliferation of endothelial
progenitor cells, thus further preventing proper endothelial
healing (Figure 2).
In vivo, the time course of endothelial healing after stent
implantation varies in different animal models. Although
in healthy pigs, endothelialization is similar between BMS
and DES at 28 days,48 a clear delay of endothelialization in
both sirolimus- and paclitaxel-eluting stents was observed
in a rabbit iliac-overlapping DES implantation model.46 In
view of distinct differences with respect to vessel wall
reactivity after stent implantation between animals and
humans, however, these results cannot be applied entirely
to the situation in humans. After BMS implantation,
near-complete endothelialization has been suggested to
occur by 3 to 4 months.6 A morphological autopsy study
comparing coronary segments from patients after DES and
BMS implantation revealed delayed arterial healing and
poorer endothelialization after DES compared with BMS
implantation of similar duration (Figure 3).7 Indeed, in 23
DES patients in that study, 14 had evidence of late-stent
thrombosis, and of these 14 patients, 13 died of a DES-
related cause.7 Thus, current evidence suggests delayed
reendothelialization and arterial healing after implantation
of DES compared with BMS, resulting in potentially
Figure 1. Rapamycin and paclitaxel
increase tissue factor (TF) expression. Pac-
litaxel enhances c-Jun NH2-terminal kinase
(JNK) phosphorylation, which in turn leads
to an increase in TF protein expression
and TF surface activity. The PI3-kinase
and its downstream target, the mammalian
target of rapamycin (mTOR), inhibit endo-
thelial TF expression; rapamycin inhibits
the mammalian target of rapamycin, which
leads to a disinhibition of (and thus an
increase in) TF expression and surface
activity. MKKs indicates map kinase
kinases (upstream regulators of JNK);
PI-3K, phosphatidylinositol-3 kinase.
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enhanced thrombogenicity (Figure 4). It is uncertain
whether reendothelialization with DES is only delayed or
persistently incomplete up to late time points. It is unclear
in atherosclerotic human arteries how long it will take for
DES to endothelialize. We have shown that in humans,
delayed healing is common with current DES and that in
those that thrombose, other factors, such as hypersensitiv-
ity reaction, bifurcating and ostial stenting, penetration of
Figure 2. DES reduce neointima forma-
tion but may increase stent thromboge-
nicity. Effect of sirolimus-eluting/
paclitaxel-eluting stent strut on the local
vessel wall after implantation. Sirolimus/
paclitaxel reduces neointima formation
by inhibiting vascular smooth muscle
migration and proliferation (green
arrows). However, the drugs also inhibit
reendothelialization, induce tissue factor
(TF), and may prevent homing and prolif-
eration of endothelial progenitor cells
(EPCs; red arrows/bars).
Figure 3. Delayed reendothelialization after DES implantation. Time course of arterial healing in BMS, Taxus DES, and Cypher DES
from 1 to 8 months after stent implantation. Although some peristrut inﬂammation is observed in BMS at 1 month, complete arterial
healing, including a well-established neointimal layer, is seen at 3 and 8 months’ duration. Taxus DES shows early ﬁbrin deposition sur-
rounding stent struts (*), which persists up to 8 months, as a sign of delayed healing. In contrast, Cypher DES shows predominance of
inﬂammatory cells, including giant cell formation (black arrowheads), at early time points (1 and 3 months), whereas ﬁbrin deposition is
stronger at 8 months.
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a necrotic core, stent malapposition, and restenosis, may
also be important predictors of thrombosis.
There is compelling evidence that certain subsets of pa-
tients have a favorable long-term outcome after implantation
of DES, which results in a reduced need for interventional or
surgical revascularization due to sustained suppression of
neointimal growth. Factors associated with greater healing
from our experience include shorter stent length, less plaque
area, less fibrin deposition, and greater endothelialization.
Other factors that may influence healing are likely to be
patient-related, such as antiplatelet therapy discontinuation,
renal failure, diabetes mellitus, and a lower ejection fraction,
which have all been reported in clinical studies.14 Further-
more, there is variability from patient to patient even in
wound healing; the response to drug also varies, with some
patients requiring a lower drug dose for equivalent benefit.
Thus, many factors influence the healing process and vary
with individual risk factors.
Risk Factors for Different Time Points of
DES Thrombosis
Stent thrombosis may occur acutely (within 24 hours of stent
placement), subacutely (up to 30 days after stent implanta-
tion), as late thrombosis (after 30 days), or as very late
thrombosis (after 12 months). The most important risk factors
for acute and subacute stent thrombosis are primary stenting
in ST-segment elevation myocardial infarction and acute
coronary syndromes.20,26 Additional risk factors include stent
length, congestive heart failure, and a prothrombogenic state,
such as metastatic cancer.19,20,26,27 One of the most significant
risk factors for late and very late stent thrombosis appears to
be discontinuation of antiplatelet therapy.26,27 Other predic-
tors are stent underexpansion and residual reference segment
stenosis.19,27
Design of Future DES
The stent coating influences thrombogenicity. Whether a
simple chemical coating, such as titanium-nitride-oxide, that
diminishes platelet adhesion and fibrinogen binding com-
pared with stainless steel will be effective against restenosis
and stent thrombosis remains to be elucidated in large clinical
trials.57 Coating of stents with substances that potentially
facilitate reendothelialization may represent a novel therapeu-
tic approach. For example, in preliminary studies, coating of
stents with CD34 antibodies designed to “capture” endothe-
lial progenitor cells proved to accelerate endothelial coverage
and appeared safe and feasible in humans.58 Similarly, stents
loaded with an integrin-binding cyclic Arg-Gly-Asp peptide
accelerated endothelialization by attracting endothelial pro-
genitor cells in a porcine model.59 Further studies are needed
to assess the long-term efficacy and safety of these biologi-
cally active stents. Furthermore, a combination of “proheal-
ing” substances (such as vascular endothelial growth factor)
with established “antirestenosis” drugs may represent an
interesting approach to obtain the benefit of reduced resteno-
sis without the cost of an increased risk for stent thrombosis.
Considering the delay in healing along with the unknown
time of reendothelialization of current DES, prohealing strat-
egies such as the use of peroxisome proliferator–activated
receptor- agonists, which not only diminish inflammation
but also enhance endothelialization, may also represent an
interesting new approach for DES.60 Given the importance of
tissue factor in the initiation of coagulation and thrombosis,
we also proposed dimethyl sulfoxide as a novel coating
strategy for DES.61 Dimethyl sulfoxide prevents vascular
smooth muscle cell proliferation and migration, ie, the key
mechanisms of restenosis; at the same time, dimethyl sulfox-
ide inhibits tissue factor upregulation in endothelial cells,
vascular smooth muscle, and monocytes and prevents throm-
botic occlusion in a mouse carotid injury model.61
Conclusions
The pathogenesis of stent thrombosis is still not fully under-
stood. A combination of factors may be involved, including
procedure-related factors, patient-related factors, and lesion
Figure 4. Temporal sequence of reendo-
thelialization in BMS and DES.
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characteristics. With DES, biological properties such as
thrombogenicity, ie, induction of tissue factor, inhibition of
reendothelialization of the stented segment, and distal endo-
thelial dysfunction may increase the risk beyond that seen
with BMS. Because premature cessation and resistance to
antiplatelet drugs is associated with subacute and late DES
thrombosis, prolonged dual-platelet inhibition must be con-
sidered, especially in high-risk patients, balanced against the
risk of bleeding.
With nearly 6 million DES implanted, and in view of the
high morbidity and mortality associated with it, stent throm-
bosis is an important healthcare issue that requires further
clinical study. Consistent with this interpretation, the US
Food and Drug Administration issued a statement acknowl-
edging the importance of the increasing concern with respect
to DES thrombosis. There was consensus that the on-label use
of DES may be associated with a small increase in stent
thrombosis compared with bare-metal stents, but that it does
not lead to an increased risk of death or myocardial infarction,
and that under these conditions, the benefits of DES outweigh
a possibly increased risk for stent thrombosis62; the panel left
open the possibility, however, that off-label use of DES (ie,
use of DES outside the FDA-approved indications) may
indeed be associated with an increased risk of death or
myocardial infarction compared with the use of BMS owing
to an increase in the rate of stent thrombosis.62
Statements that second-generation DES appear to be less
prone to stent thrombosis and thus “safer” than first-
generation DES appear equally premature because the same
uncertainty with respect to long-term safety prevails. Addi-
tional in vitro studies of compounds used on DES and
autopsy studies of patients with DES dying of cardiac and
noncardiac causes would help in understanding the mecha-
nisms of stent thrombosis. Moreover, large-scale, non–
corporate-sponsored registries and clinical trials are needed to
reliably assess the “true” risk of stent thrombosis with DES.
Control of data by non–corporate-sponsored data analysis
centers under the auspices of the American Heart Associa-
tion/American College of Cardiology/European Society of
Cardiology, including cardiac surgeons, cardiologists, inter-
nists, and cardiac pathologists, is a prerequisite to the unbi-
ased evaluation of current and future DES technologies.
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